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Immunization Against Chlamydia trachomatis Infection of the Genital Tract with Antigen 
Pulsed Dendritic Cells
H O
Research Advisors: Vemon R. Grund, Ph.D. and Harlan D. Caldwell, Ph.D.
Chlamydia trachomatis is an obligate intracellular bacterium that infects epithelial cells 
o f the ocular and genital mucosa. C. trachomatis infection of the genital mucosa are a 
leading cause of sexually transmitted disease (STD). Chlamydial genital infection in 
women results in infertility and is a major risk factor for the transmission of HIV. A 
vaccine to prevent chlamydial infection is needed but has proven difficult to produce 
using conventional vaccination approaches. Potent protective immunity to vaginal re­
challenge in a murine model of chlamydial genital infection has only been achieved by 
infection or by immunization with dendritic cells (DC) pulsed ex vivo with whole 
inactivated organisms. This immunity correlates with a chlamydial specific CD4 Thl 
immune response although the precise effector mechanisms of this immunity are not 
known. To better understand the potent immunizing properties o f chlamydial pulsed DC 
the expression o f DC surface antigens (Ags), chemokines, chemokine receptors and 
cytokines were investigated. Inactivated chlamydial organisms were found to have the 
capacity to stimulate upregulation of Ag presentation and costimulatory molecules, 
chemokines and chemokine receptors important for cellular migration, and cytokines that 
mediate a Thl immune response. Because o f the potent anti-chlamydial immunizing 
properties of DC, it was hypothesized that DC could be a powerful vehicle for the 
delivery of individual chlamydial Ags that are thought to be targets for more 
conventional vaccine approaches. The chlamydial major outer membrane protein 
(MOMP) was investigated as a target Ag. The results demonstrate that recombinant 
MOMP (rMOMP) pulsed DC secrete large amounts o f IL-12 and stimulate infection 
sensitized CD4+ T cells to proliferate and secrete high levels of IFN-y. Therefore, the 
rMOMP pulsed DC were primed to drive a MOMP-specific Thl immune response. 
Interestingly, adoptive immunization with rMOMP pulsed DC generated a Th2 biased 
immune response and immunized mice were not protected following infectious 
challenge. It was concluded that the delivery o f MOMP to DC for immunization is a 
plausible approach to determine the protective capabilities of MOMP; however, the 
plasticity of DC and the nature of the immunogen will require additional measures to 
stimulate the appropriate type of immune response.
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GLOSSARY OF ABBREVIATIONS
Ag = antigen
APC = antigen presenting cell 
BCA = B cell attracting chemokine 
BCR = B cell receptor 
CC, CXC = chemokine 
CD = cellular differentiation marker
CD3 = cellular differentiation marker 3 (T cell receptor complex)
CD1 lb = cellular differentiation marker I lb  (macrophage, dendritic cell marker) 
CD 19 = cellular differentiation marker 19 (B cell marker)
CD28 = cellular differentiation marker 28 (costimulation)
CD40 = cellular differentiation marker 40 (costimulation)
CD86 = cellular differentiation marker 86 (B72 molecule, costimulation)
CCR = chemokine receptor (CCR1 -8 )
CXCR = chemokine receptor (CXCR1-5)
D = C. trachomatis serovar D 
DC = dendritic cell
DMEM = Dulbecco's Modified Eagles Medium 
EB = elementary body
ELISA = enzyme linked immunosorbent assay
FACS = fluorescence activated cell sorter
GM-CSF = granulocyte/macrophage-colony stimulating factor
HK EB = heat killed elementary bodies
I-Ab = major histocompatibility complex Class II murine gene loci 
IFN-y = interferon-gamma(Thl cytokine)
IFU = infection forming units 
Ig = immunoglobulin
IgGl = immunoglobulin gamma-isotype I (Th2 antibody)
IgG2a = immunoglobulin gamma-isotype 2a (Th 1 antibody)
IL-I = interleukin-1
IL -1RA = interleukin-1 receptor antagonist 
IL-2 = interleukin-2 (Thl cytokine)
IL-4 = interleukin-4 (Th2 cytokine)
IL-6 = interleukin-6
IL-10 = interleukin-10 (Th2 cytokine)
IL-12 = interlekin-I2(Thl cytokine)
IL -12p35 = interleukin-12 subunit 35kD
IL-12p40 = interleukin-12 subunit 40kD
IMDM = Iscove’s Modified Dulbecco’s Medium
iNOS = inducible nitric oxide synthase
i.p. = inlra-peritoneal
IP-10 = interferon induced protein-10
i.v. = intravenous
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KO -  gene knock out
LB = latex beads
LC = Langerhans cells (skin EXT)
LN = lymph nodes 
Ltn = lymphotactin 
LPS = lipopolysaccharide (endotoxin)
MAb = monoclonal antibody
MBP = maltose binding protein
MCP = monocyte chemotactic protein
M-CSF = macrophage-colony stimulating factor
pH-/- = p  heavy chain knock out (B cell knock out mice)
MHC = major histocompatibility complex (antigen presentation)
MHC I p2 -/- = major histocompatibility complex p; knock out (blocks CD8 expansion) 
MHC II P -/- = major histocompatibility complex p chain knock out (blocks CD4 expansion) 
MIF = macrophage inhibitory factor 
MIP = macrophage inflammatory protein 
MOMP = major outer membrane protein
MoPn = mouse pneumonitis (mouse adopted strain o f C. trachomatis)
NK cell = natural killer cell
Nonprofcssional APC = non-professional antigen presenting cells (i.e., epithelial cells) 
Professional APC = professional antigen presenting cell (i.e., DC, macophages)
RANTES = regulated on activation, normal T  cell expressed and secreted
RB = reticulate body
rMOMP = recombinant MOMP
RPA = RNase Protection Assay
s.c. = subcutaneous
STD = sexually transmitted disease
TCA-3 = T  cell activation gene
TCR = T  cell receptor
TCR a  -/- = T  cell receptor a  chain knock out (aP  T  cell knock out mice)
TCR 5 -/- = T  cell receptor 8 chain knock out (y5 T  cell knock out mice)
TEM = transmission electron microscopy
Thl response = Thelper type 1 immune response (IFN-y, IL-I2. IgG2a)
Th2 response = T helper type 2 immune response (IL-4, IL-10, IgGl)
TN F-a = tumor necrosis factor-alpha (Thl cytokine)
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Chapter 1: Background and Introduction
The genus Chlamydia includes four species: C. trachomatis, C. psittaci,
C. pneumoniae and C. pecorum (1,2). C. trachomatis and C. pneumonia are 
predominantly human pathogens while C. psittaci and C. pecorum typically infect birds 
and large animals. C. trachomatis is the leading cause of preventable blindness in 
developing countries and a major cause of sexually transmitted disease (STD) worldwide 
(3). Chlamydial infection in the genital tract of women can ascend to the upper regions 
causing salpingitis that potentially leads to ectopic pregnancy or tubal infertility (4-6). 
Other significant health problems include urethritis and epididymitis. There is a 
correlation between genital infection and the increased transmission of human 
immunodeficiency virus (HTV) indicating C. trachomatis as a risk factor (2). C. 
pneumoniea, also a human pathogen, causes acute respiratory diseases such as 
pneumonia, bronchitis and sinusitis. Recently, C. pneumoniae infection has been 
correlated with coronary heart disease (7, 8).
C. psittaci is a common pathogen to all bird species and, although rare, can infect 
humans who work with the organism or handle birds. Transmission occurs via inhalation 
of aerosolized droplets. Psittacosis has a wide range of severity from asymptomatic 
infection to flu-like symptoms to lethal respiratory complications (2). C. pecorum also 
rarely infects humans and mainly leads to disease in animals.
Human C. trachomatis infections are a major cause o f STD. Various ideas for 
preventing and controlling STD have been generated by the medical and political
l
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communities. Behavioral changes have been suggested yet implementing social change is 
very difficult. Physicians strive for better diagnosis and subsequent treatment with 
antibiotics but unfortunately 50% of infected persons are asymptomatic thus the disease 
goes unrecognized and untreated (2). Research scientists striving to develop topical 
microbicides have demonstrated cytotoxicity to various organisms such as Chlamydia 
trachomatis, herpes simplex virus, Neisseria gonorrhoeae and HIV in cell culture; 
however, prevention of infection in animal models has yet to be achieved (9).
Although antibiotic treatment effectively eradicates chlamydial infection, the 
preponderance of asymptomatic infection somewhat precludes this mode of therapy for 
all infected persons. In addition, antibiotics do not necessarily eliminate an infection that 
has already had the opportunity to progress to chronic disease. Development of an 
alternative pharmacological tool, such as a vaccine, is an attractive avenue for control and 
prevention of sexually transmitted chlamydial diseases.
Life Cycle of Chlamydia
Chlamydia are defined as Gram-negative bacteria due to the presence of an inner 
cytoplasmic membrane and an outer membrane although they are devoid of the 
characteristic peptidoglycan layer between these membranes of the cellular envelope (2). 
These bacteria are obligate intracellular parasites that potentially lead to a variety o f 
chronic diseases. Chlamydia are successful and complex parasites due to their unique 
developmental life cycle which is comprised of two metabolically and fUnctionally
2
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distinct stages. The small, infectious and metabolically inactive elementary bodies (EBs) 
are able to survive in the extracellular environment long enough to transmit infection from 
one host cell to another. EBs bind to and are rapidly internalized (10) by eukaryotic cells 
into membrane-bound inclusions whereupon they transform during the first two hours 
postinfection into the larger and metabolically active form termed reticulate bodies (RBs). 
At 8 to 12 hours postinfection the RBs begin to increase in size and beyond 12 hours 
they undergo replication by binary fission within inclusions. After 18 hours, the 
expanded RBs differentiate into new infectious EBs leading to lysis of the host cell 
(between 36 and 72 hours) and release o f infectious organisms to surrounding cells 
thereby facilitating the spread of infection (II).
Chlamydia and Host Cell Interactions
Binding and internalization of EBs is an extremely efficient process (10) and years 
o f extensive studies suggest that chlamydial protein components enable the EBs to bind 
to host cells and initiate phagocytosis by typically non-phagocytic cells such as mucosal 
epithelial cells. Progress towards identifying such chlamydial proteins has been hindered 
by the fact that there are no genetic systems available for chlamydia (12, 13). Despite 
these challenges, the major outer membrane protein (MOMP) which makes up 
approximately 60 % o f the chlamydial cell wall (14) has come forward as a strong 
candidate involved in EB and host cell interactions. MOMP has been suggested to play a 
vital role in adherence of chlamydia to host cells (15), therefore it is intimately involved in
3
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pathogenesis, and it is an immunodominant antigen recognized by the host during 
chlamydial infection (16).
Antisera to EBs neutralize infectivity in a serotype-specific fashion (2, 17) and 
MOMP is reported to be the predominant serotyping antigen (18). MOMP contains 
eight transmembrane (outer membrane) domains with four extracellular loops termed 
variable domain (VD) I through IV (19). Specific monoclonal antibodies to negatively 
charged VD I or II and IV block attachment o f EBs to cells suggesting MOMP’s 
involvement in electrostatic interactions necessary for the chlamydial organism to bind to 
the host cell. It has been shown that VD IV contains a conserved hydrophobic domain 
that is inaccessible to antibody on native EBs suggesting it lies within a structural pocket. 
Thermal disruption o f this domain inhibits attachment of EBs implying that MOMP VD 
IV might modulate essential hydrophobic interactions with the host cell during the 
infection process (19).
Studies using a recombinant maltose-binding protein (MBP)-MOMP fusion show 
MBP-MOMP can competitively inhibit EB binding to host cells (15). Additionally, 
MBP-MOMP binding to cells is inhibited by heparin or heparin sulfate suggesting that 
MOMP binds to heparin sulfate receptors on host cells (15). However, MBP-MOMP is 
not internalized by the host cells. It is plausible that MOMP mediates chlamydial 
binding to host cells while a separate, unknown component of the EB may initiate 
internalization. Nonetheless, it is widely believed that MOMP plays an important role
4
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as a cytoadhesion and is one of possibly many surface components that initiate 
chlamydial pathogenesis.
C. trachomatis
The C. trachomatis biovariants are made up of two human pathogens, trachoma 
and lymphogranuloma venereum (LGV) strains, and a mouse pathogen, mouse 
pneumonitis (MoPn) strain (2). Trachoma strains infect human squamocolumnar 
epithileal cells (serovars A to K.) with infection typically occurring at and localized to the 
genital or ocular mucosa (17). LGV is comprised of serovars L 1, L2 and L3 and leads to 
systemic illness (17). LGV strains colonize epithelial cells but invade submucosal tissues 
such as lymph node cells. MoPn infects mouse mucosal cells and remains localized, 
therefore it is similar to trachoma biovars. The mouse model utilizing MoPn has been the 
most thoroughly studied and characterized o f the various animal models for respiratory 
and reproductive tract C. trachomatis infections. MoPn shares 95% sequence homology 
with the human C. trachomatis serovar D (20). The mouse model for chlamydial infection 
and disease of the female genital tract closely parallels human genital infection (21-24). As 
a result of the availability of inbred strains o f mice, genetically defined K.O mice and 
numerous mouse immunological reagents, valuable knowledge has come forth regarding 
infection and immunity.
5
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Immunology of chlamydial infection
Immunity is the state o f protection from infectious disease and is comprised o f 
innate and acquired immunity. Innate immunity is inborn, nonspecific and incapable o f 
memory responses (25). It is the first line of defense to resist infection until either 
infection is quickly resolved or acquired immunity develops. Innate immunity consists of 
four types o f defensive barriers: anatomic (skin, mucosa), physiologic (temperature, pH, 
chemical mediators), endocytic/phagocytic (neutrophils, macrophages/monocytes, NK 
cells) and inflammatory barriers (vasodilation, edema, influx o f phagocytes) (25). These 
nonspecific, innate mechanisms rarely eradicate infection alone but they are essential for 
orchestrating the adaptive response by recruiting lymphocytes and antigen presenting 
cells. An intact immune system that can both specifically recognize and selectively 
eliminate infection is essential for acquired immunity. Acquired immune responses, 
unlike innate immunity, are adaptive and have the following characteristics: antigenic 
specificity, diversity, immunologic memory and self/nonself recognition (25). Due to 
these adaptive attributes, acquired immunity is the target for development of vaccines and 
consists of two major components, humoral and cell-mediated immunity.
Humoral Immunity
Humoral immunity is driven by antibodies that specifically bind unprocessed 
antigens and possess multiple functions for controlling infection. Antibodies are 
immunoglobulin proteins consisting o f two identical heavy chains and two identical light
6
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chains that recognize a specific epitope on antigen (26). Immunoglobulins are either 
present on the B cell membrane and/or secreted by plasma cells. Immunoglobulins (Ig) are 
divided into five isotypes based on their heavy chain: IgM, IgD, IgG, IgA and IgE (26). 
Initial antibody-mediated responses are typically of the IgM isotype which can bind 
multiple epitopes due to its ten antigen binding sites. IgM antibodies can destroy or 
opsonize target antigens by efficient complement fixation. IgM precedes production o f 
the other isotypes that are predominantly involved in a memory response. IgD secretion 
is believed to induce TCR expression and augment T helper function. IgG (IgG-1,-2a,- 
2b,-3). the most abundant isotype in the serum, functions primarily by complement 
fixation. IgA antibodies are secreted into bodily fluids and capable o f eliciting immunity 
at the mucosal surface. IgE antibodies bind receptors on basophils and mast cells leading 
to allergic inflammatory responses (26).
Critical events during B cell differentiation occur between the pro- and pre- B cell 
stages whereupon genetic rearrangement produces the IgM heavy (pH) chain allowing 
formation o f cell-surface IgM receptors and development of the pre- B cell (27). Without 
the intact pH chain, IgM cannot form and B cell differentiation is halted at the pro- B cell
stage (27). The essential nature of the pH chain has been exploited to study the role of 
antibody-mediated immunity to both primary and secondary C. trachomatis infections. 
Neonatal mice treated with anti-p antibodies, thus suppressing B cells, were able to 
resolve chlamydial infection comparable to controls as well as show protection upon
7
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reinfection indicating that antibody-mediated immunity is not a key player in protective 
immunity to chlamydia (28). This type of B cell suppression is incomplete hence a small 
portion o f B cells could theoretically function in immunity. To more thoroughly 
investigate the role of antibody-mediated immunity, knock out (K.O) mice lacking the p.
gene (jiMT/pMT mice) were studied. It was observed that p. gene K.O mice are also able 
to clear chlamydial infection comparable to wild type mice and exhibit complete 
protective immunity upon vaginal re-challenge (29).
Mice (pMT/p.MT) that lack chlamydial-specific antibodies, however, did show an 
increased susceptibility to re-infection suggesting that specific antibodies at the genital 
tract may be involved with preventing colonization (29). Although local chlamydial 
antibodies such as secretory immunoglobulin A (slgA ) have been associated with 
decreased shedding of Chlamydia in the gene knockout work and other related work, they 
do not appear to be essential for clearance of a primary or secondary infection (30. 3!). 
Thus slgA appears to have a subordinate role in acquired protective immunity to genital 
chlamydial infection.
Cell-Mediated Immunity
T cells are the key players in cellular immunity. Unlike B cells, T cells have 
antigen receptors expressed on the cell surface specific for recognition of processed 
antigenic peptides on antigen presenting cells (25). Most T cells (~90%) have a T cell
8
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receptor (TCR) comprised of a disulfide-linked heterodimer consisting of an a  and a (3 
chain. These chains are considered members o f the Ig superfamily and undergo genetic 
rearrangements of variable (V), joining (J) and diversity (D) genes to provide multiple 
antigenic specificities (25). A small subset of T cells (-10%) have y and 8 chains which are 
structurally similar to the a (3 TCR; however, the yS T cells have fewer germ-line gene 
elements which limit their antigen recognition repertoire (25). Although the y5 T cells are 
few in number, they predominate at mucosal sites such as the gut epithelium. This led to 
an investigation of whether the y8 T cells are involved in chlamydial infection and 
immunity as compared to a [3 T cells. Mice with the inactivated gene for the TCR a  chain 
do not clear chlamydial infection while KO mice for the 8 chain resolved infection with 
similar kinetics o f normal animals indicating a critical role for aP  T cells in the immune 
response (32).
T cells (aP) function as either regulatory or effector cells depending upon their 
phenotype. CD4+ T helper (Th) cells regulate immune responses in several ways 
including secretion of cytokines and the activation of B cells to produce antibodies (25) (33). 
CD8+ cytotoxic T cells (Tc) act as effectors by killing antigen bearing cells through either 
perforin or Fas-mediated pathways. Some activated CD4+ Thl cells can also exercise 
cytotoxic capabilities through Fas ligand/Fas receptor interactions with target cells (25).
To assess the necessary T cell phenotype to resolve and protect against chalmydial 
infection, monoclonal antibodies were produced to either CD4+ or CD8+ T cells. Results
9
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
from these types o f studies prove to be highly variable thus compounding any definitive 
conclusions (34-36). Other approaches employing adoptively transferred T cell clones to 
athymic mice illustrate the importance of both CD4+ and CD8+ T cells in protective 
immunity, however higher efficiency was observed in mice receiving transfer of CD4+ cells 
(34). In further investigation o f a CD4+ versus a CD8+ T cell response, polyclonal CD4+ 
and CD8+ T cells isolated from the spleens o f mice post primary infection with C. 
trachomatis were adoptively transferred to naive mice. Those administered polyclonal 
CD4+ T cells, but not those given CD8+ T cells, expressed protective immunity (37). 
Therefore, it has been demonstrated that CD4+ T helper cells play a major role in 
expediting protection while CD8+ cytotoxic T cells carry a minimal role.
Alternative approaches that block clonal expansion o f either CD4+ or CD8+ T 
cells have also been utilized to characterize the T cell phenotype involved in C. 
trachomatis infection. It is well established that CD8+ cytotoxic T cells respond to 
antigenic peptides presented on MHC I molecules (MHC I-restricted ) on antigen 
presenting cells (APC). Recognition of antigenic peptides leads to engagement o f the 
TCR-antigen complex driving clonal expansion of CD8+ T cells (38,39). Alternatively, 
CD4+ Th cells are activated by MHC II-presented Ags (MHC II-restricted ) on APC with 
subsequent CD4+ T cell expansion. KO mice with inactivated gene encoding the p2 ■
microglobulin subunit o f the MHC I molecule cannot stabilize the necessary interaction 
between MHC I at the APC cell surface with the antigenic peptide on the TCR of CD8+ 
cells and cannot expand CD8+ T cells. MHC II KO mice are produced by inactivating the
10
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I-Ap gene which is responsible for expression of the (3 chain, an essential component o f the
MHC II molecule for stabilizing the MHC II-antigen-TCR sandwich. Without this 
stabilized interaction, CD4+ T cells will not expand. Studies in mice lacking either 
properly functioning MHC I (Class I) or MHC II (Class II) revealed that resolution of and 
subsequent protection against chlamydial re-infection requires MHC II-restricted CD4+ T 
cell responses while mice lacking a CD8+ response are able to clear genital infection 
similar to normal mice (40).
Although strong evidence exists for T helper activity, a role for CD8+ cytotoxic T 
cells was further examined in cytolysis or apoptosis deficient mice produced by gene 
targeting. Perforin is a pore-forming protein secreted by cytotoxic T cells that perforates 
target cell membranes and permits entrance of granzyme proteases that degrade DNA 
leading to apoptotic death o f the target cell (25). Another mechanism for cytotoxicity is 
through Fas ligand (CD95L) found on activated CD8+ and CD4+ T cells (25). Fas ligand 
binds Fas receptors (CD95/TNFa-receptor family) on target cells transducing a signal that 
results in apoptotic cell death. Mice lacking genes for either perforin, Fas, Fas ligand or 
both perforin and Fas ligand each demonstrated complete resolution o f chlamydial 
infection at the genital tract and protective immunity (41). These results clearly rule out 
any necessity of either a CD4+ or CD8+ mediated cytotoxic response. Studies that 
contribute to our overall understanding of the immunology of chlamydial infection are 
summarized in Figure 1.1.
II
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Cytokines
Antigen recognition by and subsequent clonal activation of CD4+ Th cells results 
in their expansion, producing cells that are all specific for a particular antigen-MHC II 
complex. These CD4+ Th cells then secrete intercellular signals (proteins) termed 
cytokines. It is the cytokine profile of these cells that dictate bias towards a Thl (type 
1-T helper) or Th2 (type 2-T helper) response (33). A Thl response is typically 
characterized by the secretion of IFN-y, IL-2, IL-12 and TNF-a with activation o f 
macrophages, cytotoxic T cells and IgG2a production (Figure 1.2) (33). High levels of 
IFN-y. IL-12 and IgG2a are found in the murine model for C. trachomatis infection hence 
indicate a Thl polarized response and is correlated with clearance of C. trachomatis and 
offering protection against an infectious challenge (32.42). The secretion o f IFN-y by Thl 
cells also has an inhibitory effect on the Th2 pathway by suppressing IgGl secretion (33). 
Th2 cells secrete IL-3, IL-4, IL-5, IL-10 and activate B cells, eosinophils and mast cells. 
IL-4 and IL-10 not only activate Th2 but also inhibit the Thl response (33). For example, 
IL-4 activates Th2 cells by priming B cells to undergo class switching from IgM to IgGl 
and concomitantly blocks IgG2a production.
Cytokine production upon chlamydial infection has been extensively studied to 
further elucidate the specific T helper pathway. Secretion of IL-6, IL-10, IL-12, TNF-a
and IFN-y by splenic CD4+ T cells isolated from mice post resolution of chlamydial
12
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infection has been consistently reported (37, 43). Studies employing various strains of 
KO mice that are deficient in these cytokines have been useful in assessing the importance 
o f individual cytokines in resolution of, and protection against, chlamydial genital 
infection.
IL-6 is a major immune and inflammatory mediator that targets B lymphoblasts as 
well as stimulates T cell proliferation. IL-6 has also been reported to regulate IgA (an 
antibody to many mucosal antigens) production that led to studies o f the potential role of 
IL-6 in mucosal immunity to chlamydia. Data from IL-6 KO mice demonstrate that IL-6 
is not required for production of IgA at the genital mucosa that target chlamydial antigens 
nor is IL-6 required for resolution of chalmydial infection (44).
IL-10 is a regulatory cytokine produced upon chlamydial infection and serves to 
dampen the Thl response, while IL-12 production enhances a Thl response (32,33). 
Anti-IL-12 treatment in mice slows clearance of chlamydial infections at the genital tract 
suggesting that IL-12 is a key cytokine although these mice eventually clear infection (32). 
Production of TNF-a stimulates T cells to produce IFN-y and drives both B cell
proliferation and IgG2a production. It has been shown that the TNF-a cytotoxic 
pathway inhibits chlamydial growth both in vilro and in vivo (45, 46). However, TNF-a 
is not required in resolution o f chlamydial infection (44).
IFN-y secretion activates macrophage function and blocks cytokine dependent B
cell differentiation and proliferation. IFN-y drives a strong preference to the Thl pathway
13
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by both activating Thl cells and simultaneously inhibiting Th2 cells. IFN-y is a key 
cytokine in host defense due to its inhibition o f indoleamine 2,3-dioxygenase (47-49) that 
depletes tryptophan, an essential amino acid for chlamydial replication. However, IFN-y 
KO mice surprisingly clear 99.9% o f  genital chlamydia by 3 weeks postinfection but 
develop systemic disease in several organs (32). This suggests that IFN-y is an essential 
factor for preventing dissemination o f chlamydial organisms and persistent infection. 
IFN-y also induces nitric oxide (NO) production that provides an anti-bacterial effect via
damage to cell membranes, proteins and nucleic acids by free radicals. Although inducible 
nitric oxide synthase (iNOS) is detected locally and systemically during chlamydial 
infection, studies with mice deficient in the iNOS gene show that iNOS is not needed to 
resolve infection (32).
Overall, the data suggest that genital infection is controlled by CD4+ Th cells in an 
IL- 12-dependent and IFN-y-independent manner. Despite this essential immunological 
information and years of scientific research towards vaccine development against C. 
trachomatis, an efficacious vaccine against genital infection has not been developed.
Development of Chlamydial Vaccines
Zhang, et al. demonstrated marginal success using DNA immunization with the C. 
trachomatis MOMP gene (OmpA) in a mouse lung model (50). This group reported that 
intramuscular immunization with the gene encoding MOMP elicited a Thl polarized
14
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response and IgG2a production with significant but incomplete protection upon lung 
challenge with infectious MoPn (50). In contrast, it was recently reported that this 
vaccination strategy applied to a genital tract model evoked a somewhat weak cellular and 
humoral immune response and offered no protection upon genital challenge (51). The 
reasons underlying the differential success in the lung versus the genital tract utilizing a 
DNA based vaccine is yet to be understood. Do these two anatomically different sites 
require tissue specific immune mechanisms or different protective antigens?
The first successful vaccination against chlamydial genital tract infection in a 
mouse model was carried out by Su et al (52). The immunization strategy employed 
murine bone marrow-derived dendritic cells (DC) pulsed ex vivo with heat killed 
chlamydial EBs that were adoptively transferred to naive mice. This vaccination elicited 
an immune response that was nearly identical to mice that had cleared a primary infection 
with viable organisms and are known to be highly resistant to secondary re-challenge.
The potent chlamydial-specific CD4+ immune response favored the Thl pathway (high 
levels of IL-12, IFN-y, IgG2a) and for the first time demonstrated protection against a 
primary genital tract challenge with MoPn (52). The observed protection was equal to 
that of postinfected mice. These findings demonstrate that viable organisms are not 
necessary to evoke anti-chlamvdial protective immunity at the genital mucosa, although 
delivery o f killed chlamydiae alone (without using DC as a delivery system) does not 
elicit protection. These results strongly suggest that the DC vehicle for antigen is critical 
for protection against chlamydiae at the genital mucosa. This DC based vaccine approach
15
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was utilized by a separate lab studying a murine model for chlamydial respiratory 
infection and was able to successfully produce protective immunity against C. 
trachomatis in the lung (53).
Dendritic cell vaccination is early in its development and it is currently an 
impractical approach to prevent infectious diseases in humans. However, more 
conventional methods of vaccination against chlamydia have failed to offer protection at 
the genital mucosa, while succeeding in the lung, lead us to believe the dendritic cell is a 
potentially unique vehicle and instrument for development of genital immunity. The 
underlying molecular mechanisms that enable chlamydial pulsed DC to successfully drive 
potent protection at the genital tract site is not understood and has yet to be extensively 
characterized. Further pursuit to unravel the DC biology and the elicited immune 
response to the chlamydial organism or its protective antigenic components is justified.
Exploiting Dendritic Cells for Immunotherapy
Dendritic cells (DC) are sentinels of the immune system and professional antigen 
presenting cells (APC) that efficiently initiate an immune response upon antigenic insult 
(54). Proliferating DC progenitors originate in the bone marrow and are released into the 
bloodstream as non-proliferating DC precursors. These precursors then differentiate into 
immature/interstitial DC and reside in the peripheral tissues as highly efficient phagocytes 
(54). Immature DC are known to readily capture Ag by phagocytosis o f particulate 
matter such as latex beads (55), bacteria, viruses (56), apoptotic bodies and necrotic
16
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cellular debris (57). DC capture these antigens through either macropinocytosis, Fc 
receptors (FcRe and FcRy), mannose receptors, C-type lectin receptors (DEC-205) or
engulfment of apoptotic bodies and necrotic cellular debris. The characteristic 
cytoplasmic projections extending from the DC surface are thought to play a role in both 
phagocytosis of particles as well as migration through the lymphatic system. The 
immature DC phagocytize and process antigens but are inefficient at antigen presentation. 
However, upon antigen uptake the DC begin to mature and migrate out o f the peripheral 
tissues via the afferent lymphatics to the lymphoid organs whereupon they down- 
regulate their capacity for antigen uptake and up-regulate expression o f class II (MHC II) 
and costimulatory molecules (B7-1, B7-2, CD40) enabling efficient antigen presentation 
and subsequent activation of Ag-specific T cells (54. 58). Activation o f  these Ag-specific 
T cells is carried out by the mature DC, termed interdigitating DC, which display Ag 
within the lymph nodes and spleen (59).
Antigens processed through the exogenous pathway typically lead to presentation 
of antigenic peptides onto MHC II while antigens originating in the cytosol are processed 
and presented onto MHC I molecules (38, 39). Presentation on MHC II. accompanied 
by costimulation, leads to the activation o f Ag-specific T helper cells; likewise, 
presentation on MHC I can activate cytotoxic lymphocytes (25, 38). DC and 
macrophages have been shown to take up exogenous Ag and present antigenic peptides on 
both MHC II and MHC I which is known as 'cross priming’ (60). This unique crossover 
capacity of both DC and macrophages is not fully understood but studies by Shen et al
17
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(61) demonstrate that ovalbumin protein (OVA) pulsed DC present OVA peptides onto 
MHC I by traveling through the following pathway: phagosome -> cytosol -> 
proteasome -> ER -> Golgi -> cell surface presentation -> activation o f T-T hybridomas 
specific for OVA peptides on MHC I. From a teleological perspective, it would make 
sense that more arms of the immune system could be alerted by this 'cross priming’ 
within APC, such as DC and macrophages, which play such a critical role in regulating the 
immune response. This unique capacity also allows presentation o f  peptides derived 
from engulfed apoptotic bodies onto MHC I for recognition by cytotoxic T lymphocytes 
(CTL). Although DC and macrophages have many similar capabilities. DC are set apart 
from other professional APC because they are (i) the only APC that can activate naive T 
cells and. (ii) are able to drive T cell activation with a much higher potency (50-100X).
The ability of DC to traffic to the lymphoid organs is key to their function as 
initiators of the immune response, therefore it is essential to understand for optimization 
of their use in vaccination strategies. Inflammatory signals such as LPS or TNF-a induce 
DC migration to the lymphoid organs in vivo (58) and in chemokine gradient 
microchambers in vitro (62). Several chemokines have been shown to control DC 
trafficking from the periphery to the lymph nodes such as M IP-la, MCP and RANTES
(63-65). Chemokines are small proteins containing four conserved cysteines which form 
critical disulphide bonds. The chemokine family is categorized according to the position 
o f these cysteines: the first two cysteines are adjacent in the “CC” chemokine subfamily
18
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while the cysteines are separated by one amino acid in the “CXC” chemokines (66). 
Responses to chemokines are mediated through seven transmembrane-spanning G protein 
coupled receptors reported to be on DC and various other leukocytes (66). DC have been 
shown in vitro to express the chemokine receptors CCR1, CCR2, CCR5, CCR6, CCR7, 
CXCR1, CXCR2, CXCR4 and C5aR (64).
DC at various stages of development have the ability to migrate throughout the 
body in a highly regulated and organized fashion. As DC precursors, the cells migrate out 
of the bone marrow and circulate through the bloodstream to the peripheral, nonlymphoid 
tissues. Upon reaching their destination, typically epithelial and skin surfaces, immature 
DC are encouraged by chemokines to stay localized to the periphery where they become 
“resident DC” or “interstitial DC." The predominant chemokine responsible for 
localizing the DC to the periphery is MIP-3a (macrophage inflammatory protein) which 
binds to the chemokine receptor CCR6 on immature DC (62). DC can produce their own 
chemokines such as MIP-3a which, along with several other pro-inflammatory mediators 
(ie.. IL-1. TNF-a), have been suggested to recruit circulating DC out of the bloodstream 
upon exposure to Ag (67). Studies at the bronchial epithelium have shown a drastic 
accumulation of DC within one hour from the bloodstream to the site o f Ag exposure 
(68). CCR6 is also expressed by memory T cells and yd T cells. Both cell types have 
been shown to respond to MIP-3a (69) through CCR6, thereby enabling the recruitment 
of additional cellular players from the bloodstream to the site of infection.
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The levels of CCR6 begin to decline and/or receptor desensitization occurs as 
immature DC phagocytose Ag (62. 70). Concomitantly, an upregulation o f CCR7 occurs 
which responds to the ligands 6Ckine (secondary lymphoid-tissue chemokine. SLC) and 
MIP-3P (62, 71). The chemokine 6Ckine is expressed along lymphatic vessels and 
facilitates migration through the lymphatics to the secondary lymphoid tissue (72). MIP- 
3(3 is produced within the lymph nodes at the T cell zone area and not only attracts 
maturing DC but also naive T cells and B cells (73). Collectively, the decreased 
responsiveness to MIP-3a allows resident DC to escape the peripheral tissues,
meanwhile the increased responsiveness to 6Ckine and MIP-3(3 attracts the DC through
the lymphatics to the nodes and spleen (Fig. 1.3). Once in the lymph nodes MIP-3P
further attracts DC through the paracortical region to increase the likelihood o f DC-T cell 
interactions (62). The critical nature of CCR7 and 6Ckine for cellular trafficking to the 
nodes is demonstrated by CCR7 loss of function studies revealing deficiencies in both DC 
and T cell homing to the secondary lymphoid tissues (74, 75).
DC not only respond to chemokines from other cell sources via their ligand 
specific receptors, but they also produce chemokines to attract subsets of T cells and 
monocytes (66). For example. RANTES is a very potent chemoattractant for memory T 
cells while M IP-la  and MIP-ip attract CD8+ and CD4+ T cells, respectively (66).
Thus, the identification of chemokines, chemokine receptors and cytokines expressed by 
chlamydial pulsed DC that potentially enhance DC migration to the lymphatics and drive
20
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Th 1 -mediated protective immunity may offer the needed direction for vaccine 
development.
The mechanism by which dead chlamydial organisms are able to initiate DC 
mediated responses has not been extensively characterized. Furthermore, if dead 
chlamydial organisms can provide protection, what about chlamydial proteins or DNA? 
This prompts the consideration of chlamydial DNA and/or recombinant protein vaccines 
delivered by DC. The hypothesis to be tested is that the use of ex vivo activated 
bone marrow-derived dendritic ceils will serve as a vaccine delivery system to 
assess potential protective antigens against chlamydial genital infection in a 
mouse model. One of the most likely candidates to begin these studies is the major 
component of the chlamydial cell wall, MOMP, due to its antigenic immunodominance 
and cytoadhesion capabilities. A more complete understanding of the potential 
capabilities o f chlamydial pulsed DC for antigen delivery could result in new information 
regarding vaccine approaches against other infectious diseases and malignancies that do 
not respond to a classical vaccination strategy'. In addition, such work could contribute 
knowledge regarding potential protective antigens as well as enhance our understanding of 
effector immune mechanisms at the genital mucosa.
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The specific aims of this study are to: 
A. Extensively characterize chlamydial pulsed DC
1. Define culturing conditions to establish enriched (>95%) immature and mature DC as 
determined by phenotypic markers utilizing FACS analysis and examine shifts in CD 
antigens necessary for costimulation and presentation post treatment with heat killed 
(HK) MoPn EBs
2. Determine differential gene expression of selected chemokines, chemokine receptors 
and cytokines by DC in the presence of HK MoPn EBs by RNase Protection Assay 
(RPA).
3. Evaluate DC trafficking upon HK MoPn treatment as determined by an in 
vivo migration assay.
B. Establish delivery of MOMP fusion protein versus MOMP DNA to DC.
1. Employ immunofluorescence microscopy to characterize phagocytic uptake and 
processing o f recombinant MOMP (rMOMP) fusion protein.
2. Deliver MOMP plasmid DNA to DC (electroporation, cationic liposomes or viral 
vectors) then assay expression of MOMP by immunofluorescence.
3. Determine whether MOMP antigens presented on the DC surface are able to 
stimulate proliferation of infection sensitized T cells and cytokine production.
C. Immunize mice with DC pulsed with rMOMP or MOMP DNA.
22
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1. Characterize subsequent immune response by ELISA, T cell assays, and Western Blot 
analysis.
2. Administer infectious challenge to immunized animals to assess protection.
23
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Figure 1.1. A summary of collective studies in the literature 
describing the immune response required for the clearance of 
chlamydial infection in a murine model. This diagram summarizes the 
relevance of individual cell types necessary for the clearance of chlamydial 
infection as shown by knock out (KO) and monoclonal antibody (MAb) 
studies in mice. See glossary for definitions of listed abbreviations.
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Thl and Th2 Pathways
Figure 1.2. Summary- of Thl and Th2 pathways. This diagram 
summarizes the key cytokines secreted by T helper type I (Thl) and T 
helper type 2 (Th2) cells and the overall cellular events that follow. Note 
that red arrows indicate inhibitory interactions and green arrows indicate 
stimulatory interactions. For the purposes of this work, please note that 
Thl responses are typically indicated by T cell secretion of IFN-y and B 
cell production (T helper mediated) of IgG2a antibodies. Th2 responses 
are indicated by T cell secretion of IL-4 and IL-10 and B cell production (T 
helper mediated) of IgG 1 antibodies.
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Figure 1.3. The critical role of chemokines in DC migration and 
function. This illustration shows the origination and migration o f DC 
precursors, localization of immature DC to the peripheral tissues, and DC 
maturation and migration following immunostimulus. Chemokines and 
chemokine receptors play a critical role in differentiation, maturation and 
migration of DC. Diagram from Banchereau. et al (Annu. Rev. Immunol. 
2000. 18: 767-811.
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Ligand Receptor Function
M IP -la
M IP-lp
MIP-2
CCR1, CCR5
CCR5. CCR8*
CCR8*
chemoattract immature DC 
and activated CD8 T cells
chemoattract activated CD4+ 
T cells, activate macrophages
chemoattract CD4+, CD8+
T cells
M IP-3a CCR6 chemoattract immature DC, 
memory T cells, y5 T cells
MIP-3P CCR7 chemoattract mature DC 
through nodes, attract naive T 
cells and B cells
MCP-1 CCR2 regulate expression of 
integrins, chemoattracts and 
activates monocytes
IP-10 CXCR3* chemoattract IL-2 activated 
T cells
RANTES CCR1, CCR3, 
CCR4, CCR5
chemoattract immature DC 
and memory T cells
Figure 1.4. Summary of chemokine ligands, their corresponding 
receptors and functions. *Receptors only found on T cells.
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Figure 1.5. DC lineage pathways. Differentiation o f DC precursors to 
various types of DC according to the cytokine environment and presence 
of immunostimulus. Diagram from Banchereau. et al (Annu. Rev. 
Immunol. 2000. 18: 767-811.)
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Figure 1.6. Inducing factors and functional properties of DC 
maturation. A summar\' of the inducing factors and cellular events during 
DC differentiation and maturation. Diagram from Banchereau. et al (Annu. 
Rev. Immunol. 2000. 18: 767-811).
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Chapter 2: Materials and Methods
Generation, Culture, Enrichment and FACS o f  primary BmDC
Bone marrow-derived dendritic cells (BmDC) were generated from C57BL/10 female mice 
(6-12 weeks old) using a modified version o f the Inaba technique (76). Briefly, mice were 
sacrificed and femurs were removed, bone marrow cells were flushed from femurs and 
cultured in IMDM (GIBCO BRL) supplemented with 10% FBS, 10 ug/ml gentamicin 
sulfate. 10 ng/ml GM-CSF and 1 X 103 U/ml IL-4 (PharMingen) at 2 X 106cells/ml in 
100mm tissue culture dishes at 37° C with 5% COi. On day 3 of culture, nonadherent 
cells were removed and fresh medium containing GM-CSF and IL-4 was added. On day 5 
of culture. DC were panned by incubation at 37° C for at least 2 h then repeated for 
another 2h to remove adherent macrophages. The DC were further purified (>95% 
purity) by density gradient centrifugation with 14.5% metrizamide solution (Sigma) in 
cell culture medium. DC purity was characterized by cell size, dendritic morphology by 
phase microscopy, and viability assessed by trypan blue exclusion. DC populations 
were further characterized phenotypically for purity by FACS analysis after staining 
with anti-I-Ab, anti-CD86, anti-CD40 and anti-CDl lb mAbs for resolution of DC. DC 
cultures were also analyzed after staining with anti-Grl. anti-CD3. anti-CD19 and anti- 
Pan NK. MAbs for detection of any contaminating granulocytes. T cells. B cells, NK 
cells, respectively.
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Pulsing DC
Day 5 DC were enriched by density gradient centrifugation to >95% purity based upon 
cell size, morphology and FACS analysis. Enriched DC were plated in 4 ml of IMDM- 
10 supplemented with 10 ng/ml GM-CSF at 2.5 X 106 DC/well in 6 well tissue culture 
plates. Treatment groups are as follows: (1) IMDM alone. (2) 10 ng/ml LPS (E. coli 
strain 026:B6, Sigma), (3) Latex beads (2.5% solids-latex. 0.585 microns diameter, 
Polysciences, Inc.), (4) Heat killed MoPn chlamydial EBs (heat inactivated at 56° C for 
30 min) at MOI of 25. Treatments were added directly to the cells, mixed well, and 
incubated at 37° C for 2h, 12h, 24h, or 48h.
RNase Protection Assay for Chemokines/Receptors and Cytokines
DC total RNA was harvested by the TriZol method at 2h, 12h. 24h and 48h post 
treatment (Life Technologies RNA Isolation Protocols). Multi probe RNase Protection 
Assay (RPA) System (PharMingen) was employed to detect DC expression of M IP-la, 
M IP-ip. MIP-2, MIP-3a. MIP-3|3, MCP-1. Ltn (lymphotactin). eotaxin. RANTES. IP- 
10. TCA-3, CCR1, CCRlp, CCR3, CCR4. CCR5, CCR6, CCR7. IL -la . IL-lp. IL-1RA. 
IL-6. IL-10, IL-12p35, IL-12p40, IL-18, IFN-y, TNF-a, MIF and constitutive genes 
(internal controls) L32, GAPDH. Briefly, DNA templates (encoding exonic sequences of 
the genes of interest) fused to a T7 promoter were used for T7 RNA polymerase-directed
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synthesis of highly specific J2 P- labeled antisense RNA probes. Labeled RNA probes 
were hybridized in excess overnight at 56° C with 4 |ig target DC mRNA. The following
day, free probe and other single-stranded RNA molecules were digested with RNases T1 
and A. The remaining "RNase-protected” probes were purified, resolved on denaturing 
polyacry lamide gels based upon size and imaged by autoradiography. Protected probes 
at the appropriate sizes represent specific DC mRNA.
In Vivo DC Trafficking Assays
Day 5 DC were panned 2X (2h), enriched by density gradient centrifugation to >95% and 
labeled with a fluorescent tracer (PKH2-2, Sigma) that inserts into cellular membranes. 
Briefly. 2 X 107 DC were extensively washed with IMDM to remove FBS and stained for 
5 minutes in PKH2-2 staining solution. The staining reaction was stopped by adding 
100% serum and the cells were washed 4X with IMDM-10 to remove unbound dye. The 
cells were then viewed by immunofluorescence microscopy for approximate percent and 
pattern of DC staining and viability was assessed by trypan blue exclusion. Upon 
establishment of DC staining with PK.H2-2. day 5 enriched and stained DC were either 
(1) irradiated (3,000 Rad), (2) pulsed with IMDM or (3) pulsed with heat-killed MoPn 
EBs (MOI=25) overnight then 5 X 105 DC in 40fil o f  PBS was injected into the hind 
footpad of C57BL/10 mice. Mice were sacrificed 48h post injection and popliteal nodes 
were harvested. A single cell suspension of lymph node (LN) cells was made and density
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gradient centrifugation of the LN cells was performed to enrich for DC. The DC were 
then analyzed by immunofluorescence microscopy for number of fluorescent cells 
indicating DC migration to the lymph nodes.
Pulsing DC with Recombinant MOMP
Day 5 DC were panned 2X (2h) and enriched by density gradient centrifugation. 
Predominantly immature (highly phagocytic) DC populations (5 X 106 DC in 1 ml 
IMDM-10) were incubated in the presence of 0. 0.06 pg, 0.6 pg , 6 pg and 60 pg of
MBP-MOMP colloid spheres (30-40nm) for lh  at 37° C with shaking every 15 min. The 
cells were then centrifuged, washed gently 2X with IMDM-10 and plated in 4 ml 
IMDM-10 + GM-CSF (10 ng/ml) overnight. The following day, the cells were fixed in 
methanol and stained with murine 33b MAb ( MoPn specific MAb to MOMP) then 
stained with a secondary FITC conjugated goat anti-mouse IgG antibody and viewed by 
immunofluorescence and confocal microscopy for internalization o f MOMP spheres.
Electroporation o f  DC with MOMP DNA
Enriched DC were electroporated at 150 volts to 450 volts to generate a killing curve to 
assess the necessary voltage to produce 40-60% killing (trypan blue exclusion) which is 
optimal for successful transfection of cells with DNA (BioRad Gene Pulser II Instruction 
Manual). Briefly, cells are placed on ice for 10 min, pulsed with a given voltage, placed 
on ice for another 10 min, pulsed again at the same voltage then allowed to recover on ice
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for >10 min. Between 300 and 400 volts, approximately 50% of the DC were killed. Live 
DC were enriched by density centrifugation while dead cells were removed. The cells 
were then monitored over the next 24h for survival to determine whether this method is 
practical for transfection purposes.
Transfection o f  DC with MOMP DNA
DMRIE-C Reagent (GIBCO-BRL) is a 1:1 (M/M) liposome formulation o f the cationic 
lipid DMRIE (1,2 -dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide) 
and cholesterol in membrane-filtered water. The DMRIE-C cationic lipid reagent 
interacts spontaneously with negatively charged DNA to form lipid-DNA complexes that 
penetrate cell membranes for efficient, transient transfection of suspension cells. The 
protocol is as follows: 6 well plates were prepared with 500 pi OPTI-MEM I (GIBCO- 
BRL) per well plus either 0, 2. 4, 8 or 12pl o f DMRIE-C reagent and mixed by swirling 
the plate. 4 pg of plasmid (containing SV40 and CMV promoters) DNA containing
OmpA gene (encoding MOMP) was added to each well. Samples were incubated at room 
temperature for 30 min then cationic liposome-DNA complexes were allowed to form. 2 
X 106 DC in 200 pi IMDM (serum-free) were added to each well and incubate at 37° C 
C 0 2 incubator for 4 h. After 4 h, 2 ml o f IMDM supplemented with 15% FBS was 
added. Cells were fixed in methanol at 4, 12, 24 and 48 h and stained with murine 33b 
MAb and stained with a secondary FITC conjugated goat anti-mouse IgG antibody and
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viewed by immunofluorescence. In addition, lysates from transfected DC were run on 
SDS-PAGE for Western blot analysis using the murine 33b MAb to detect expression of 
MOMP by the transfected cells.
Infecting and culturing fem ale CS7BL/10 mice
At ten days and seven days before infecting mice, 2.5 mg/mouse of Depo-Provera 
(Pharmacia & Upjohn) was injected by s.c. to synchronize estrous cycles. To infect, 5 pi
sucrose phosphate glutamate (SPG) containing chlamydial EBs was injected into the 
vaginal vault. For infecting C57BL/10 mice, either 150, 1,500 or 15,000 infection forming 
units (IFU) of MoPn EBs were injected. At three days post infection, mice were cultured 
by swabbing the vaginal vault (Calgi-swab, 8 rotations left/right). Swabs were placed 
into the corresponding tubes, on ice. containing 600 pi SPG and 2 sterile glass beads.
Samples were vortexed vigorously and then 200 pi was removed from each sample and 
transferred into a 96 well "dilution plate". Serial dilutions (1:10) were then made from 
each sample. HeLa cells (in 96 well flat bottom plates) were inoculated in triplicate for all 
dilutions. After the inoculum was been added to the HeLa cells, the plates were 
centrifuged for lh at 700 x g then rocked at 37° C for 30 min. Cells were washed with 
Hanks Balanced Salt Solution (HBSS) 3X and fed 100 pi Minimal Essentials Medium
supplemented with 10% FBS (MEM-10) and cyclohexamide (10 ng/ml) per well.
Cultures were incubated for 24 hours (MoPn) then fixed in methanol. Primary Ab
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staining was carried out with murine MAb EVI HI (specific for chlamydial LPS) and 
secondary staining with FITC conjugated goat anti-mouse IgG. Stained cultures were 
viewed by immunofluorescence and recoverable IFU/sample were determined. Culturing 
was performed at intervals postinfection (days 3, 5, 7, 14, 21, 28) until the infection was 
resolved. In parallel with culturing time points, mice were sacrificed, genital tracts 
removed and fixed in formalin, and stained for histopathology to determine infiltrating 
cells/inflammation (Histo-Path of America, Millersville, MD). Ten days after the mice 
had cleared the infection, vaginal secretions and sera were obtained for Ab analysis by 
ELISA. Additionally, at 60 days postinfection, the genital tracts were removed for gross 
pathological evaluation and scored for the presence of hydrosalpinx (Histo-Path of 
America. Millersville. MD).
Indirect Enzyme Linked Immunosorbent Assay (ELISA)
Round bottom 96 well microplates (Immulon 2, Dynatech) were coated with 10 (ig/ml of
formalin fixed EBs in 50 mM Tris buffer, .15M NaCl (pH 7.5) and placed at 4° C 
overnight. The following day. the plates were washed with Tris buffer containing .05% 
Tween 20 to remove unbound antigens. Wells were blocked using 2% BSA in Tris buffer 
containing .05% Tween 20 for 2h at 37° C. Serial dilutions of mouse sera and vaginal 
washes were made in buffer (2% BSA in Tris buffer, .05% Tween 20). The diluted sera 
and vaginal washes were added to the Ag coated plates for 1.5h at 37° C. The plates were 
washed extensively with PBS-Tween buffer and alkaline-phosphatase (AP) secondary Ab
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was added for an incubation period o f lh and 15 min at 37° C. The secondary Abs 
employed were the following: AP rabbit anti-mouse IgG-y (Zymed), AP goat anti-mouse 
lgG2a (Southern Biotech Associates), AP goat anti-mouse IgGl (Southern Biotech 
Associates), AP-goat anti-mouse IgA (Southern Biotech Associates). The plates were 
again washed extensively and 100 |il o f substrate (5 mg o P-nitrophenyl phosphate
(Sigma)/10 ml buffer), was added. The plates were incubated 15-45 min and optical 
density read at 405 nm.
Direct (Cytokine) Enzyme Linked Immunosorbent Assay (ELISA)
Purified anti-cytokine “capture antibodies" were diluted 1:250 ( 2 ug/ml) in .05M Tris 
buffer. .15M NaCl (pH 7.5) and 100 |il used to coat 96 well microplates overnight at 4°
C. The plates were then washed to remove unbound antibodies. Blocking solution (2% 
BSA in TBS-Tween 20) was added for 2 h at 37° C. Next, cytokine standards for IL-4, 
IL-6. IL-10, IL-12 and IFN-y (PharMingen) and supernatants (from APC + T cell 
cultures) were added to the plates overnight at 4° C. The next day, 100 (il of biotin- 
labeled anti-cytokine "detection antibodies" (1:250. 2 (ig/ml) were added and incubated at 
37° C for 1 h. The plates were washed extensively and 100 jj.1 o f alkaline phosphatase- 
avidin (2 fig/ml) added for 45 min at 37° C. Plates were washed again and 100 |il of
substrate (5 mg o P-nitrophenyl phosphate (Sigma)/10 ml buffer) was added. The plates 
were incubated 15-45 min and optical density read at 405nm.
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T cell Proliferation Assays
Spleens from infection sensitized mice were harvested and a single cell suspension made 
in PBBS-5% FBS. Magnetic CD90 (Thy 1.2), CD4 (L3T4) or CD8a (Ly-2) microbeads 
(Miltenyi Biotec) were utilized for positive selection of total T cells, CD4+ T cells or 
CD8+ T cells, respectively. T cells from mice that have resolved infection and are 
protective following adoptive transfer were plated in round bottom 96 well plates at 3 X 
1 CP cells/well. Day 5 enriched DC that had been pulsed overnight (ie.. with rMOMP) 
were then harvested and incubated with the infection sensitized T cells at 1 X 104 DC per 
well thus giving a 1:30 ratio o f DC to infection sensitized T cells. 48 h later 1 |iCi o f 3H-
thymidine (78.4 Ci/mmol. LIFESCIENCE-NEN) was added to each well. Radioactive 
cultures were incubated overnight at 37° C and counts per minute (cpm) measured (Top 
Count plate reader) to assess thymidine uptake/incorporation. Note: standard Antigen 
Presentation Assay controls were used (T cells alone; APC alone; T cells + APC; T cells 
+ APC + antigen); differentiated DC serve as the antigen presenting cells (APC) and are 
non-proliferating cells.
Adoptive Immunization with pulsed DC
Female C57BL/10 mice (6-12 wks) were used as bone marrow donors, DC were 
propagated and enriched by the modified Inaba (76) procedure discussed above. Mice (5 -
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8 per treatment group) were adoptively immunized by s.c., i.p. or i.v. (1-7 X 106DC in 
HBSS/mouse) with either of the following: ( 1) no treatment = naive group, (2) unpulsed 
DC, (3) DC pulsed with HK MoPn EB (MOI=25) for 12, 24 or 48 h, (4) HK MoPn EB 
in HBSS (given the same number o f HK EB as group 3), (5) DC pulsed with rMOMP 
and (6) DC pulsed with MBP alone. A booster immunization was administered 14 days 
after the initial immunization. Serum IgGl. IgG2a and IgA levels were measured by 
ELISA to ascertain the IgG isotype o f the immune response elicited by the immunized 
mice. IgA and total IgG (7) levels in vaginal secretions were also measured by ELISA.
One week following the booster immunization mice were injected by s.c. with 2.5mg 
Depo-Provera per mouse at day -10 and day -7 to synchronize their estrous cycles prior 
to an infectious challenge. One week following the second Depo-Provera injection, mice 
were administered an infectious, vaginal challenge with chlamydial MoPn ( 150 or 1,500 
IFU. ID50= 10 or 100 respectively). Protection was assessed by performing cervico- 
vaginal swab cultures. Briefly, the vagina was swabbed, samples were placed in SPG, 
samples were vortexed. serial dilutions of samples were used to infect monolayers of 
HeLa cells to determine the number of infectious organisms being shed on days 3, 5, 7, 14, 
21.28 (and each following week until infection was resolved). Cultures were incubated at 
37 C for 24 h, fixed with methanol, and stained with the murine MAb EVI HI specific to 
chlamydial LPS and IFU counts determined by immunofluorescence. The total 
recoverable IFU per sample was determined by the following equation: IFU/sample = (# 
of fields)(dilution factor)(original sample volume/inoculum volume).
39
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Western Slot Blot Analysis
MoPn EB lysates (100 |ig total protein) were electrophoresed on a SDS-PAGE mini-gel 
using BioRad SDS Running Buffer for Ih at 180 V. Proteins were transferred to 
nitrocellulose membrane (NCM) using 350mA (constant) for 1 h in 1:5 diluted phosphate 
transfer buffer (60.35 gm/L sodium phosphate dibasic, anhydrous, and 10.33 gm/L 
sodium phosphate monobasic, monohydrate). The NCM was blocked with PBS + 3% 
BSA. .05% Tween-20 for 2 h to overnight. The NCM was placed in the Mini-Protean II 
apparatus (BioRad, multichannel apparatus) with the antigen side facing upward. Sera 
from immune, normal, DC + HK EB immunized, DC + rMOMP immunized or DC + 
MBP immunized mice were added for 2 h to overnight at 37° C. An anti-mouse MAb 
(33b) specific to MOMP was included as a positive control for localizing the MOMP. 
The NCM was washed several times and secondary antibodies (goat anti mouse IgG2a- 
AP. IgG 1-AP or IgG3-AP) were diluted 1:200 and added for 2 h. The NCM was washed 
and developed using Western Blue Stabilized Substrate for Alkaline Phosphatase 
(Promega).
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Chapter 3: Characterization of Chlamydial Pulsed DC.
FACS Analysis o f  Chlamydial Pulsed DC:
A modified version of the Inaba (76) technique was utilized to culture murine bone 
marrow-derived DC followed by panning and density gradient centrifugation in 14.5% 
metrizamide. This procedure produced enriched populations o f >95% DC. Bone marrow 
cultures (myeloid progenitors) treated with GM-CSF and IL-4 for 5 days differentiate 
into a mixture of cell types including macrophages, T cells, B cells, granulocytes, NK 
cells, DC precursors and immature DC. Enriched DC cultures showed positive staining 
for surface markers I-Ab (MHC II), CD86 (B7-2) and CD1 lb by FACS analysis (Fig.
3.1). Based upon the adherent property of macrophages in culture with GM-CSF, the 
panning procedure effectively separated macrophages away from non-adherent/loosely 
adherent DC. Enriched DC cultures did not show staining above background for CD3 or 
CD 19 indicating an absence of contaminating T and B cells, respectively. DC cultures 
showed negligible staining (<5%) of NK cells (Fig. 3.1).
Upon establishment of culturing techniques that provided highly enriched 
populations of DC, transmission electron microscopy (TEM) and immunofluorescence 
microscopy was used to detect the uptake of chlamydial EBs by enriched DC. At a ratio 
of 25:1 (25 beads/EBs per one DC) efficient phagocytosis o f latex beads (Fig. 3.2B) and 
nonviable chlamydial EBs (Fig. 3.2C) by DC was observed by TEM. In addition, DC 
phagocytosis of EBs is shown by immunofluorescence microscopy (Fig 3.3). The
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immunofluorescence experiments revealed 100% uptake o f chlamydiae as shown by 
positive staining for chlamydial LPS within every DC. Cytoplasmic projections 
extending from the DC surface, the hallmark DC morphology, is shown by phase 
microscopy (Fig. 3.2D). The highly granular appearance common to all professional 
phagocytes is also demonstrated by TEM (Fig. 3.2A).
Next, changes in cell surface antigens were investigated after pulsing DC with heat 
killed chlamydiae. Control unpulsed DC showed two populations for I-Ab (MHC II) 
staining: indicating immature (lower fluorescence) and mature (increased fluorescence) DC 
populations (Fig. 3.4). Thus, the culturing method produced mixed DC populations in 
regard to DC maturity. DC maturation was enhanced upon treatment with either the 
positive control (10 ng/ml LPS, E. coif) or killed chlamydiae, but not with latex beads.
DC maturation following uptake of chlamydiae is shown by a log increase in fluorescence 
for MHC II staining and a ‘A log increase for CD86 and CD40 staining (Fig. 3.4). There 
was also a marked increase in the number of cells expressing the costimulatory molecules, 
CD86 and CD40 following uptake of chlamydiae and treatment with LPS (Fig. 3.4).
RNase Protection Analysis o f  Chlamydial Pulsed DC:
The ability of DC to traffic from peripheral tissues to the draining region lymph 
nodes is critical to their immunizing capacities. This crucial function is regulated by 
chemokines, chemokine receptors and cytokines. The kinetics of DC chemokine, 
chemokine receptor and cytokine gene expression following endocytosis of chlamydiae
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was studied by using an RNase Protection Assay (RPA). The data are summarized in 
Figure 3.9. The RPA procedure is shown in Figure 3.8. The data show that MIP-la,
MIP-2, TNF-a, IL -la , IL-1 (3 and IL-1RA (IL-1 Receptor Antagonist) were expressed by 
2 h post treatment with chlamydiae, but not latex beads, and remained continuously 
expressed for 48 h (Fig. 3.5, 3.6A, 3.6B). MIP-3a and 1L-I2p40 were expressed by 12 h
and showed similar continuous expression (Fig. 3.5, 3.6A). In contrast, IP-10 (interferon 
induced protein) and IL-6 were transiently expressed being first detected at 12 h, but not 
at 48 h (Fig. 3.5, 3.6A). High levels of CCR7 expression by DC were observed under all 
conditions at 2 and 24 h post treatment, however only chlamydial pulsed DC expression 
remained high at 48 h (Fig. 3.7).
In vivo migration assays
To investigate DC migration capacities in vivo fluorescent chlamydial pulsed DC 
or fluorescent unpulsed DC were injected into the hind footpad of mice. Two days later 
the popliteal nodes were harvested, total lymph node cells were collected, and DC were 
isolated by metrizamide density centrifugation. The number o f fluorescent DC detected 
by immunofluorescence microscopy was <1% of the DC injected therefore it was 
extremely difficult to recover reasonable numbers of DC by this method. Six chlamydial 
pulsed DC were detected by immunofluorescence microscopy demonstrating DC 
migration in vivo to the pooled popliteal nodes. However, no fluorescent unpulsed DC
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were observed by immunofluorescence and therefore unactivated DC did not migrate (Fig. 
10).
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FIGURES
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Figure 3.1. Establishing Purity of BmDC Population by FACS Analysis.
DC purity was characterized by FACS analysis after staining with anti-l-Ab 
(V1MC II). anti-CD86 (B7-2). anti-CD I lb for resolution of DC. Isotvpe matched 
controls were used to determine background staining. DC cultures were also 
analyzed after staining for anti-CD3. anti-CD 19. and anti-Pan NK for resolution 
of any contaminating T cells. B cells or NK cells, respectively. The cultures are 
>95% DC as demonstrated by positive staining for all DC markers and negligible 
staining for potential contaminating cell types. Based upon the adherent property 
of activated macrophages. 2X-2 h panning procedures separate the macrophage 
population from the DC population.
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Figure 3.2. Transmission Electron Microscopy (TEM) and Phase 
Microscopy of DC. (A) TEM of unpulsed DC. (B) TEM of DC pulsed with 
heat killed chlamydial EBs at 25:1 EB to DC ratio. (C) TEM of DC pulsed with 
latex beads (LBs) at 25:1 beads to DC ratio. (D) phase microscopy of DC 
revealing the characteristic cytoplasmic projections.
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Figure 3.3. DC phagocytize EBs efficiently. DC were pulsed overnight 
with chlamydial EBs. fixed in methanol, and stained for chlamydial LPS (EVH1 
MAb). Individual DC show two staining patterns: (1) fine punctate, and (2) 
aggregate immunofluorescence staining throughout the cytoplasm. The #1 
punctate staining pattern was observed more frequently than the large aggregate 
#2 staining. 100% of the observed DC stained positively for the presence of 
chlamydiae. This staining pattern is consistent with previously published 
immunofluorescence micrographs (52). Control unpulsed DC did not exhibit 
fluorescent staining (data not shown). Size bar = 40 |im.
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Figure 3.4. FACS Analysis of Chlamydial Pulsed DC. Enriched unpulsed 
DC populations show two populations of Class II (I-Ab) staining indicating 
immature (less fluorescence) and mature (increased fluorescence) DC populations. 
DC maturation is enhanced after pulsing with either LPS (10 ng/ml. E.coli strain) 
as the standard positive control or with nonviable chlamydiae (25: 1 EB to DC 
ratio) illustrated by a log shift in fluorescence intensity for Class II staining. 
Staining for CD86 and CD40 costimulatpry molecules increases in the presence of 
LPS or chlamydiae as compared to negative controls. Latex beads were employed 
as a control for phagocytosis alone and demonstrate similar staining as the no 
treatment group.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 3.5. RPA Anlaysis of DC Expression of chemoklnes. A kinetic 
analysis of chemokine RNA expression by DC subjected to NT (no treatment: 
lanes 2. 6. 10. 14). LPS (10 ng/ml: lanes 3. 7. 11. 15). heat killed MoPn EBs (25: I 
EB to DC ratio: lanes 4. 8. 12. 16) and latex beads (25:1 beads to DC ratio: lanes 
5. 9. 13. 17). The NT group likely reflects spontaneous maturation resulting from 
cell culture alone. LPS serves as a positive control for immunostimulation. HK 
EB treatment is the experimental group and latex beads control for the effects of 
phagocytosis alone. Boxed bands represent differentially expressed genes.
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Figure 3.6A, B. RPA Analysis of DC Expression of Cytokines. A kinetic 
analysis of cytokine RNA expression by DC subjected to NT (no treatment: lanes
2. 6. 10. 14). LPS (10 ng/ml: lanes 3. 7. 11. 15). heat killed EBs (25:1 EB to DC 
ratio: lanes 4. 8. 12. 16) and latex beads (25:1 beads to DC ratio: lanes 5. 9. 13.
17). Boxed bands represent differentially expressed genes.
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Figure 3.7. RPA Analysis of DC Expression of Chemokine Receptors. A
kinetic analysis o f DC treated with NT (no treatment. lanes 1. 4. 7). MoPn HK 
OB (25:1 EB to DC ratio: lanes 2. 5. 8) and LB (25:1 latex beads to DC ratio: lanes
3. 6. 9). The increased longevity of CCR7 mRNA in chalmydial pulsed DC is 
indicated by the boxed band.
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Figure 3.8. RNase Protection Assay (RPA) procedure. In vitro transcription 
in the presence of radioactivelv labeled UTP produced labeled RNA probes which 
were used to hybridize with DC sample mRNA. RNase digestion degraded single 
stranded (non-hvbridized) RNA. The remaining double stranded RNA was 
resolved on denaturing gels and visualized by autoradiography. This outlined 
method is from the BD Phar.Vlingen manual.
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Figure 3.9. Summary of the DC kinetic expression profile of chemokines, 
chemokine receptors and cytokines. DC pulsed with nonviable chlamydiae 
differentially express the chemokines and cytokines listed above as shown by 
RPA. Activated transcription was temporally regulated as indicated by the 
columns for DC chemokine/cytokine expression during 2 to 48h. 12 to 24h, and 12 
to 48 h.
12 hrs -> 24 hrs
IP-10 
IL-6
12 hrs -> 48 hrs
MIP-3a
IL-12p40
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Treatm ent #  o f  mice_______ fluorescent DC
Irradiated DC 4 0
Unpulsed DC 4 0
DC + HK EB 4 6
Figure 3.10. Summary of data from an in vivo DC migration assay.
Mice were injected with fluorescently labeled DC into the hind footpad. 
After 48 h. the popliteal nodes were harvested and pooled within each 
treatment group. Density centrifugation (14.5% metrizamide) o f lymph 
node cells was used to enrich for DC. The recoverable DC were plated in 
tissue culture wells and viewed by direct fluorescence microscopy to 
detect injected fluorescent DC that had migrated to the popliteal nodes. 
This method resulted in an extremely low yield of recoverable DC.
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Chapter 4: Delivery of rMOMP to DC for Antigen Presentation 
DC Readily Phagocytose Recombinant MOMP and Secrete Large Amounts o f  IL-12:
Bone marrow-derived DC were pulsed with a range of concentrations ( 0 to 60 jig)
of particulate recombinant MOMP (rMOMP) for 15 min, 30 min, 1 h, 4 h, 14 h and 22 h 
to optimize uptake and detection of MOMP within the DC cytoplasm. DC 
phagocytosis of recombinant protein was determined after methanol fixation and staining 
with an mouse MAb (33b) to MOMP. Positive staining was observed by 
immunofluorescence microscopy for 5 X 104 DC pulsed with 0.6 fig of rMOMP for 1 h
(Fig. 4.1). To determine whether the rMOMP was internalized by DC, confocal 
microscopy was utilized to detect MOMP in the cytoplasm. Z- series o f images were 
digitally stacked and revealed positive staining for MOMP throughout the cytoplasm of 
DC (Fig. 4.2). Increasing the number of DC and rMOMP proportionally resulted in 
similar staining by immunofluorescence and confocal microscopy (data not shown).
As a result of expressing rMOMP the purified MOMP preparation contained 
high levels of bacterial endotoxin (-300,000 U/ml LPS). Due to the potent 
immunostimulatory effect of LPS on DC maturation (see Chapter 3 data figures), the 
contaminating LPS was not removed from the rMOMP preparations. DC pulsed with 
rMOMP produced large amounts of IL-12, a potent Thl cytokine (Fig. 4.3). In contrast, 
pulsed DC did not produce either IL-10 or IL-4, important Th2 cytokines (Fig. 4.3).
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DC Presentation o f MOMP Antigen(s) to Infection Sensitized CD4+ T Cells:
Upon establishment of efficient DC phagocytosis of rMOMP, presentation o f 
MOMP antigens (Ags) by DC was investigated next. A summary of the data is 
diagrammed in Figure 4.7. DC pulsed with rMOMP were incubated in the presence o f 
infection sensitized T cells for 48 h, then pulsed with JH-thymidine overnight. Infection 
sensitized T cells proliferated 2.5 times more in the presence of DC pulsed with rMOMP 
than unpulsed DC (Fig. 4.4). To determine whether MOMP antigens were presented by 
MHC I. MHC II or both, CD8+ T cells and CD4+ T cells were incubated with pulsed 
DC. CD4+ but not CD8+ T cells proliferated in response to rMOMP pulsed DC (Fig.
4.5). CD4+ T cell proliferation also occurred following incubation with MBP (maltose 
binding protein) pulsed DC, although at a significantly lower level than the response to 
rMOMP (Fig 4.5).
To determine the type of T cells (Thl or Th2) that were being activated in 
response to the MOMP pulsed DC, CD4+ T cells were incubated in the presence o f DC 
for 48 h and the supernatants were collected and assayed for cytokine production. DC 
pulsed with rMOMP. but not with MBP. induced CD4+ T cells to produce IFN-y, a Thl 
cytokine (Fig. 4.6). Low levels of IL-10 were detected in the presence o f either DC + 
MOMP or MBP. IL-4, another Th2 cytokine, was not detected in the supernatants (Fig.
4.6). It was concluded from these results that rMOMP (i) is efficiently phagocytosed by 
DC. (ii) stimulates DC to secrete IL-12 (iii) is processed and presented onto MHC II
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molecules, (iv) stimulates CD4+. but not CD8+. T cells to proliferate, and; (v) stimulates 
CD4+ T cells to differentially produce high levels of IFN-y.
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Figure 4.1. DC phagocytosis of rMOMP as shown by immunofluorescence 
microscopy. 5 X I04 DC were pulsed with 0.6 |ig rMOMP for 1 h at 37° C. 
washed and incubated overnight at 37° C with 10 ng/ml GM-CSF. DC were fixed 
in methanol and stained with an anti mouse MAb to MoPn MOMP and viewed 
by immunofluorescence microscopy. Arrows indicate a punctate positive staining 
pattern for MOMP epitopes along the perimeter of the DC cell surface. Negative 
controls were (i) unpulsed DC and (ii) pulsed DC stained with an isotype 
matched primary Ab to a serovar L2 MOMP and the same secondary Ab as the 
experimental group. Both controls were negative for MOMP staining (data not 
shown). Size bar = 40 (im.
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Figure 4.2. DC phagocytosis of rMOMP as shown by confocal microscopy. 5
X 104 DC were pulsed with 0.6 gg rMOMP for 1 h at 37° C. washed and 
incubated overnight at 37° C with 10 ng/ml GM-CSF. DC were fixed and stained 
with an anti mouse MAb to MOMP. Arrows indicate each individual DC 
represented as a stacked Z series of images indicating positive staining (green) for 
MOMP within numerous planes (Z axis) through the cytoplasm of the rMOMP 
pulsed DC. Unpulsed DC did not show staining for MOMP (data not shown).
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Figure 4.3. DC pulsed with rMOMP secrete large amounts of IL-12. DC
supernatants were collected 24 h after pulsing with rMOMP. Large amounts (—22 
ng/ml) ofIL-12 (Thl) was detected by ELISA. IL-10 and IL-4. Th2 cytokines, 
were not detected in the DC supernatants. Two separate experiments were each 
done in duplicate and are expressed as ng/ml +/- SD.
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Figure 4.4. Infection sensitized T cells proliferate in response to DC pulsed 
with rMOMP. Spleens from infection sensitized mice were harvested and total T 
cells collected. Infection sensitized T cells were incubated in the presence of 
unpulsed DC and rMOMP pulsed DC for 48 h. Next. JH-thymidine was added 
overnight and cpm counts were used to assess T cell proliferation. DC are non­
proliferative cells, therefore only activated T cell proliferation is observed by this 
type of APC assay (see Chapter 2). Experiments were done in triplicate and are 
expressed as mean cpm +7- SD.
64
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
\ i m i r  \
Figure 4.5. Infection sensitized CD4+ but not CD8+ T cells proliferate in
response to DC pulsed with rMOMP. Infection sensitized CD4+ and CD8+ T 
cells were collected and incubated for 48 h in the presence of unpulsed DC. DC 
pulsed with rMOMP or DC pulsed with MBP. Next. JH-thymidine was added 
overnight and cpm counts used to determine T cell proliferation. Experiments 
were done in triplicate and expressed as mean cpm +■/- SD.
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Figure 4.6. DC pulsed with rMOMP induce infection sensitized CD4+ T 
cells to differentially produce IFN-y. Infection sensitized CD4+ T cells were 
incubated in the presence of DC + rMOMP or MBP for 48 h then supernatants 
were collected. Cytokine levels in supernatants were determined by indirect 
ELISA. Experiments were done in triplicate and are expressed as mean pg/ml +/- 
SD.
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Pulsing Dendritic Cells With Recombinant MOMP
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Figure 4.7. Endocytosis, processing and presentation of MOMP by DC.
This is a schematic summary o f the data found in Chapter 4. This figure 
illustrates DC endocytosis of particulate rMOMP spheres, processing and 
presentation of MOMP Ags onto MHC II molecules and subsequent DC 
secretion of IL-12. Infection sensitized T cells recognize the presented MOMP 
Ags on MHC II via their T Cell Receptor (TCR). This interaction with the DC 
MHC II is stabilized by the T cell CD4 molecule. Proper recognition o f MOMP 
epitopes accompanied by costimulation (B7: CD28) leads to the activation of the 
CD4^ T cells to proliferate (clonallv expand) and secrete IFN-y. Both DC 
secretion ot IL-12 and T cell secretion of IFN-y indicate a potential to drive a Thl 
immune response in vivo. Therefore, the rMOMP pulsed DC were primed ex 
vivo to drive a potent MOMP specific Thl immune response upon adoptive 
immunization in mice.
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Chapter §: Immunization of mice using DC pulsed with rMOMP
Optimizing the DC Immunization:
Prior to immunization studies utilizing DC pulsed with rMOMP, optimization of 
the delivery and overall efficacy of the positive control vaccine (DC pulsed with HK EB) 
was performed. Intra-peritoneal (i.p.), subcutaneous (s.c.) and intra-venous (i.v.) routes 
o f administration were investigated for immunizing against chlamydial infection using DC 
pulsed for 12. 24 or 48 h with HK EB. The i.v. immunization (via the orbital sinus) with 
12 h pulsed DC proved to be the superior route o f administration as shown by powerful 
protection (5.6 logs) following intravaginal challenge (Fig. 5.1). There was very little 
variability among the i.v. immunized mice between days 3 and 7 (Fig. 5.2A, B), however 
some variability was observed between days 10 to 14 post-challenge (Fig. 5.2C, D). The 
majority of the i.v. immunized mice exhibited equal or higher levels of protection than that 
of infected and re-challenged mice (Fig. 5.2A-D).
Adoptive immunization by i.p., but not s.c., elicited strong protection (~3 logs) 
against chlamydiae in 3 of the 5 mice (Fig. 5.3A) on the fourth day following intravaginal 
challenge . In contrast, mice immunized by s.c. shed similar numbers of organisms as the 
naive mice at 4 days post challenge although 15 days post-challenge these mice had 
resolved infection to the same degree as the i.p. immunized group (Fig. 5.3B). Equivalent 
numbers of unpulsed DC or HK EB administered alone did not yield protection (Fig.
5.3A, B). In attempt to understand the large variability in the i.p. immunization group,
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the presence o f antibody isotypic differences in pre-challenge sera from the i.p. 
immunized mice was tested. Protected mice produced elevated levels of chlamydial 
specific IgG2a antibodies (Thl) compared to the unprotected mice (Fig. 5.4). All mice in 
the i.p. immunization group produced low levels of chlamydial specific IgGl antibodies. 
All mice in the i.v. immunized group produced both IgG2a and IgGl at approximately 
equivalent levels (Fig. 5.5A, B).
The course of infection in naive mice infected with 15,000 IFU, 1,500 IFU or 150 
IFU is shown in Fig. 5.6. The results show that 100% of the mice became infected at 
each challenge dose, shed similar numbers of organisms and resolved infection with similar 
kinetics (Fig. 5.6). Therefore, the lower infectious load (150 IFU) was selected for 
challenging the immunized mice to avoid overwhelming the immune system and possibly 
masking any low levels o f resistance post challenge. It is on this basis that the infectious 
challenge was lowered from 1500 IFU/mouse to 150 IFU/mouse for the rMOMP 
immunization experiments. In further efforts to optimize the DC vaccine approach, the 
number of DC administered was increased from I X 106 DC to 7 X 106 DC.
Immune Response in Mice Following Immunization using DC Pulsed with rMOMP:
Mice were immunized twice using 7 X 106 DC pulsed with rMOMP or MBP and 
intravaginally challenged with 150 IFU 14 days after immunization. Previous results (see 
Chapter 4) demonstrated that DC pulsed in vitro with rMOMP secreted large amounts o f 
IL-12 (Fig. 4.3) and stimulated infection sensitized CD4+ T cells to strongly proliferate
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and secrete large amounts o f IFN-y (Fig. 4.4,4.5). However adoptive immunization (i.v.)
using DC pulsed with rMOMP generated a Th2 biased immune response illustrated by 
secretion of Th2 cytokines by rMOMP vaccine sensitized CD4+ T cells (Fig. 5.7) and a 
predominance of IgGl antibodies reactive with the EB surface as detected by ELISA (Fig. 
5.5B). IgGl and IgG2a antibodies to denatured MOMP were detected in pre-challenge 
sera as shown by Western blot analysis (Fig. 5.5A).
Challenging rMOMP Immunized Mice
Following intravaginal challenge, rMOMP immunized mice were not protected 
(Fig. 5.8). The MBP control group resolved infection with similar kinetics as the naive 
animals (Fig. 5.8). Adoptive immunization by i.p. elicited marginal (1-2 logs) and very 
transient (< 7 days) protection in 3 of the 6 mice immunized. The onset of infection in 
the i.p. immunized mice was delayed by three to six days. All i.p. immunized mice 
became similarly infected by day 7 with infectious burdens comparable to naive mice (Fig. 
5.9).
Although this DC vaccine delivery system was designed to theoretically drive a 
MOMP specific Thl immune response, a Th2 response was generated following 
adoptive immunization using DC pulsed with rMOMP. It was concluded that; (i) 
infusion o f pulsed DC into the retro-orbital sinus (i.v.) is the most effective route of 
pulsed DC vaccine administration . (ii) MOMP immunized mice produce predominantly 
IgGl antibodies reactive with the EB surface, (iii) CD4 + T cells from MOMP
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immunized mice respond to EB Ag by the secretion of Th2 cytokines IL-4 and IL-10 and 
(iv) MOMP immunized mice are not protected following intravaginal challenge with 
chlamydia.
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Figure 5.1. Intravenous injection (i.v.) is the superior route of DC vaccine 
administration. Mice received either no immunization (naive) or 2X 
immunization (s.c.. i.p.. i.v.) with unpulsed DC or DC pulsed with HK EB. and 
were challenged intravaginally with chlamvdiae. Protective immunity was 
determined by quantifying the number of chlamydial IFU recovered from 
cervicovaginal swabs. Day 4 post-challenge is shown here. Triangles represent 
individual mice. The number of recoverable IFU is shown along the x axis (log 
scale). The mean recoverable logio IFU and the log|0 protection are shown to the 
right of the graph.
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Figure 5.2. Mice immunized by intravenous injection (i.v.) with chlamydial 
pulsed DC are strongly protected following intravaginal challenge with 
chlamydiae. Naive = no immunization. DC + HK EB = DC pulsed with heat 
killed chlamydial EBs. (A) day 3 post challenge. (B) day 7 post challenge, (C) 
day 10 post challenge and (D) day 14 post challenge. Triangles represent 
individual mice.
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A.
Figure 5.3. The level of protection following chlamydial challenge was 
variable in mice that received intra-peritoneal (i.p.) immunization using 
DC pulsed with HK EB. Naive = no immunization. DC = unpulsed DC. DC + 
HK EB = DC pulsed with heat killed chlamydial EBs. (A) day 4 post challenge 
and (B) day 15 post challenge. Triangles represent individual mice. Subcutaneous 
injection = s.c.
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Figure 5.4. Protection correlates with the production of chlamydial specific 
serum IgG2a antibodies in intra-pcritoneal (i.p.) immunized mice.
Measurement oflgG2a serum antibodies by ELISA in mice immunized (i.p.) vvith 
chlamydial pulsed DC prior to infectious challenge. Positive control = sera from 
infection sensitized mice. Mice # 2 and # 5 did not produce chlamydial specific 
serum lgG2a antibodies (above) and were not protected following intravaginal 
challenge with chlamydiae (Fig. 5.1). Mice #1. #3. and =4 produced serum IgG2a 
antibodies (above) and showed 2.1 logs protection following intravaginal challenge 
(Fig. 5.1).
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Figure 5.5. Antibody responses to immunization via i.v. with DC pulsed 
with HK EB or rMOMP . (A) IgGl and IgG2a antibodies specific for denatured 
MOMP were detected in pre-challenge sera from all immunized mice as shown by 
Western blot analysis and (B) IgGl. but not IgG2a. antibodies that are specific to 
the EB surface were detected in pre-challenge sera from mice immunized using DC 
pulsed with rMOMP as shown by ELISA. Mice immunized using DC pulsed 
with HK EB produce equivalent amounts of both IgG2a and IgGl to the EB 
surface. Negative controls were mice immunized with HK EB alone (no DC 
vehicle) and unpulsed DC: neither group produced chlamydial specific IgG2a or 
IgG I antibodies (data not shown). Experiments were done in triplicate. MAb to 
MOMP shows that MOMP runs as a doublet of 40 kD and 38 kD.
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Figure 5.6. Course of infection in naive mice infected with three different 
amounts of IFU of chlamydiae. Mice were infected with 15.000. 1.500 or 150 
IFU and cultured for 28 days by cervico-vaginal swabbing (day 3. 5. 11. and 21 
shown above). Recoverable chlamydial IFU is expressed as logm IFU on the v 
axis. All mice resolved infection after 21 days.
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Figure 5.7. Immunization of mice with rMOMP pulsed DC elicits a 
predominant Th2 response. CD4* T cells were harvested from infection 
sensitized mice, mice immunized 2X chlamydial pulsed DC. and mice immunized 
2X with rMOMP pulsed DC. CD4~ T cells were incubated in the presence of 
either antigen presenting cells (APC) alone (no Ag) or APC pulsed with whole EB 
Ag and supernatants were collected at 24. 48 and 72 h. Supernatants were 
analyzed by ELISA to detect levels o f IL-4 (Th2). IL-IO (Th2) and IFN-y (T h l). 
Results shown here are from 72 h supernatants. Experiments were done in 
duplicate and are expressed as pg/ml +•/- SD.
so
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
I m m u m / a t u ' i i
Nai \  v 
I n  li t l t d
A
▲
A  a \  A
▲ A  
A A
I . . n _
|) r i >! rv I h >n
i.~ vs
l ) (  U K  M i I 4.4
I X M O M  I ’ M *  4 5 4. •()
t e r \  k .  >\ , i ' j in al ' h a d d i  na
Figure 5.8. Mice immunized using DC pulsed with rMOMP were not 
protected following intravaginal challenge. Mice were given no immunization 
(naive), infected, immunized using DCpulsed with heat killed EBs (DC + HK EB). 
and immunized with DC pulsed with rMOMP (DC + MOMP) then challenged 
with 150 IFU. The number of organisms shed (log|0 scale) from the cervico-vagina 
7 days post challenge is shown on the x axis above. Triangles represent individual 
mice.
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Figure 5.9. Immunization via i.p. using DC pulsed with rMOMP elicited 
marginal and transient protection in some mice following intavaginal 
challenge. Mice received no immunization (naive) or immunized (i.p.) using DC 
pulsed with rMOMP (DC rMOMP) and challenged with 150 IFU.
Recoverable chlamydial IFU (logn, scale) is quantified at 3 and 7 days following 
intravaginal challenge and shown on the x axis. Triangles represent individual 
mice.
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Chapter 6: Discussion
A vaccine to prevent chlamydial infection is needed but has proven difficult to 
produce using conventional vaccination approaches. Potent protective immunity to 
vaginal re-challenge in a murine model of chlamydial infection has only been achieved by 
infection or by immunization with DC pulsed ex vivo with whole inactivated organisms. 
Immunity generated by infection or ex vivo antigen (Ag) pulsed DC correlates with a 
chlamydial specific CD4+ Thl immune response although the precise effector 
mechanisms of this immunity are not known. Because o f the potent anti-chlamydial 
immunizing properties of DC it was hypothesized that DC could be a powerful vehicle 
for the delivery o f individual chlamydial Ags that are thought to be potential targets for 
more conventional vaccine approaches. Here, the chlamydial major outer membrane 
protein (MOMP) was investigated as a target Ag. The overall objectives were to 
extensively characterize chlamydial pulsed DC, deliver chlamydial MOMP to DC and 
then immunize mice with DC bearing MOMP Ags to assess protection.
The mechanisms that enable chlamydial pulsed DC to successfully drive a potent 
level of protective immunity at the genital mucosa are not understood. However, there 
are several possibilities that could account for this protective immunity including (i) 
increases in DC Ag presentation and costimulatory molecules for activating naive and 
effector T cells against chlamydial Ags, (ii) alterations in chemokine and chemokine
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receptor profiles that potentially enhance DC migration and recruitment/localization of 
other important cellular players, (iii) cytokine production by DC, or by T cells activated 
by DC, that favor a Thl response, and (iv) DC activation of B cells to produce antibodies 
specific to chlamydiae.
(i) Phenotypic and Transcriptional Analysis of Chlamydial Pulsed DC
An accumulation o f literature demonstrates the importance of Ag presentation 
accompanied by costimulation . chemokines, chemokine receptors and cytokines in 
orchestrating dynamic and complex immune responses against bacteria, viruses and 
tumors. Chemokine/cytokine ligands along with their respective receptors and functions 
are summarized in Chapter 1. It was hypothesized that the extensive characterization of 
the immunomodulatory effects of killed chlamydiae on DC would potentially provide the 
necessary information for the design of more conventional methods for vaccination against 
sexually transmitted chlamydial infection. To better understand the immunizing 
properties o f chlamydial pulsed DC the following was studied; (i) changes in cell surface 
antigen expression on DC by FACS analysis, (ii) the kinetics of chemokine, chemokine 
receptor and cytokine gene expression by RNase Protection Assay (RPA) and, (iii) DC 
migration in vivo.
For several years progress in the DC field was hindered by the lack of DC 
culturing and isolation techniques. However, it is now possible to culture large numbers 
of primary DC from bone marrow or peripheral blood by inducing growth and
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differentiation with GM-CSF. DC can be induced to differentiate from myeloid 
precursors upon treatment with GM-CSF (76) or Flt-3 Ligand (77). “Skin DC,” known 
as Langerhans cells (LC), can be amplified with transforming growth factor (TGF)-(3 (78). 
Although methods have been developed to culture murine DC, it is still a challenge to 
purify DC because reliable, unique DC markers have yet to be identified. Many o f the 
DC markers (MHC II, CD80, CD83. CD86, CD I la/b, CD40, LFA-3, ICAM, Fc 
receptors, scavenger receptors, receptors for cytokines and chemokines) are also found on 
macrophages, monocytes or other cell types. In addition, there are many subsets o f DC 
and several lineages which further compounds efforts to enrich a single population o f DC 
(72). The various DC lineage pathways are summarized in Chapter 1. The results show 
successful enrichment of DC populations to >95% as shown by positive staining for 
known DC markers CD1 lb. CD86 and MHC II by FACS analysis. Although these cell 
surface molecules are also found on macrophages, the panning procedure eliminates the 
macrophages based upon the adherent nature of GM-CSF activated macrophages.
It has been well established that following Ag capture by immature DC there is a 
downregulation of receptors (CD68) for phagocytosis and a loss of adhesion 
molecules(79). The DC then upregulate MHC molecules and costimulatory molecules for 
Ag presentation and interaction with both T and B cells (54). Inducing factors and 
functional properties o f DC maturation are summarized in Chapter 1. The data show 
phagocytosis/uptake of nonviable chlamydial organisms by DCs upregulates the 
expression of MHC II, CD86 and CD40. Conversely, DC uptake of latex beads does not
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affect expression of these molecules. Thus, the act o f phagocytosis alone cannot be 
responsible for the alterations in DC surface expression o f these immunomodulatory 
molecules. Therefore, dead chlamydial organisms have the capacity to stimulate DC for 
amplified Ag presentation and costimulation thereby providing the necessary stimuli to 
initiate the immune response. This suggests that chlamydiae do not need to be viable or 
replicate to elicit a protective immune response. Moreover, these results imply that an 
EB structural component could be responsible for initiating protective immunity and may 
therefore be important in the development of an efficacious vaccine.
It is known that culturing alone or simple physical manipulation (pipetting) can 
lead to spontaneous maturation of DC. This explains the mixed population of immature 
(lower MHC II expression) and mature DC (higher MHC II expression) in the absence o f 
immunostimuli such as LPS or pulsing with heat killed EBs. Additionally, the expression 
of CCR7 by untreated DC indicates the onset o f maturation during in vitro 
culture/growth.
The E.coli LPS positive control employed herein is routinely used to drive DC 
maturation. It is not suspected that chlamydial LPS is functioning similarly due its 
dramatically less potency (100 fold) than E. coli LPS as defined by the capacity to 
activate mononuclear phagocytes (80) and induce fever. The reduced endotoxicity has 
been correlated with structural differences within the chlamydial LPS moiety. These 
differences are as follows: reduced number of fatty acids (5 rather than 6 fatty acyl 
groups), fatty acyl groups longer than C |4, normal fatty acyls groups instead of hydroxy
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fatty acids and an enlarged hydrophobic domain in the lipid A (81). The effects of 
chlamydial LPS on DC maturation were not tested because o f the difficulty in purifying 
significant amounts o f chlamydial LPS. It is currently unknown which chlamydial 
components are responsible for DC maturation and will require further studies. It was 
recently shown that chlamydial heat shock protein 60 (hsp60) activates 
monocytes/macrophages and endothelial cells (80). Perhaps chlamydial hsp60 also 
activates DC and potentially leads to DC maturation.
The ability o f chlamydial pulsed DC to migrate to the nodes and spleen is crucial 
for localizing the DC to the appropriate cellular players (T and B cells) to generate a 
protective immune response against chlamydia. The data show that nonviable chlamydia 
induce the immunomodulatory genes that encode M IP-la , MIP-2, MIP-3a, TNF-a, IL-
la ,  IL-ip, IL-1RA IP-10, IL-6, IL-12p40 and CCR7. These gene products have been
shown in other systems to affect DC migration and interaction with other cells. It was 
found that nonviable EBs induce DC to migrate to the lymph nodes in vivo, are potent 
transcriptional activators of DC and the induced gene expression is temporally regulated. 
The kinetics o f chemokine, chemokine receptor and cytokine gene expression are 
summarized in Chapter 3.
Knowledge o f this gene expression profile may increase our understanding o f the 
DC immunizing properties. The chemokine M IP-la binds to CCR1 and CCR5, which
are found on immature DC, monocytes, activated T cells and macrophages. M IP -la  is
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chemotactic for immature DC, monocytes and T cells while serving as an activation signal 
for macrophages to become cytotoxic against tumor targets. MIP-2, on the other hand, 
binds CCR8 which is only expressed on CD4+ and CD8+ T cells. DC expression of 
these two chemokines may allow recruitment of activated T cells to the site of infection 
or naive T cells toward Ag bearing DC to aid in the response against chlamydiae. MIP- 
3a binds CCR6 to induce migration of CD34+ derived DC, memory T cells and y5 T cells 
from epithelial surfaces (69). Differential expression of MIP-3a by chlamydial pulsed 
mature DC may attract immature DC that have recently sampled Ag towards the nodes 
where the mature DC have already migrated. Also, memory T cells and y5 T cells could 
be drawn towards chlamydial Ag bearing DC for activation. The expression o f IP-10 by 
chlamydial pulsed DC suggests an ability to chemoattract activated T cells. This 
chemokine binds the CXCR3 receptor which is found on IL-2 activated T cells. This 
chemokine has recently been reported to chemoattract B cells, monocytes and NK cells as 
well (82).
Immature DC have been shown in other systems to express the following 
chemokine receptors: high CCR1, CCR2, CCR4, high CCR5, high CCR6 (LC), CXCR1, 
CXCR4 and low CCR7 (refer to Chapter 1 for ligands to these receptors). Mature DC 
downregulate the aforementioned receptors and strongly upregulate CCR7 enabling DC to 
bind 6Ckine and MIP-3p which will induce migration toward the secondary tissues. High 
levels of CCR7 expression by DC were observed under all conditions at 2 and 24 h post
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treatment indicating that DC maturation is occurring with or without immunostimulus. 
High levels o f CCR7 without immunostimulus likely reflect spontaneous maturation from 
cell culturing techniques. CCR7 expression remains high at 48 h for chlamydial pulsed 
DC however expression is no longer detected in unpulsed DC or DC pulsed with latex 
beads. This stable expression of CCR7 by chlamydial pulsed DC may extend the 
longevity of DC maturation thereby increasing DC migration into the T cell zone o f the 
lymph nodes for eliciting an immune response against chlamydiae.
The cytokines IL -la  and IL-1(J expressed by chlamydial pulsed DC are known 
mediators of inflammation and could therefore be responsible for initiating innate immune 
responses following antigenic insult. IL-IRA (which binds the IL-1 receptor with 
antagonist activity) expressed by chlamydial pulsed DC could serve to balance this innate 
inflammatory response thereby preventing an overreaction to chlamydial infection. DC 
expression of TNF-a, another pleiotropic cytokine, has been found to chemoattract 
immature DC as well as activate DC to maturity. It has also been implicated in the 
recruitment of DC from the bloodstream to the vaginal and cervical epithelium upon 
chlamydial infection . Immune responses to either chlamydial infection or vaccination 
with pulsed DC have been correlated with a strong Thl bias thus the expression o f IL- 
12p40 by chlamydial pulsed DC may function in skewing the immune response toward a 
Thl phenotype.
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It is important to note that other chemokines such as RANTES and MCP are 
expressed without a stimulus other than continuous cell culture. This would suggest that 
there are different degrees or levels o f DC maturity that are controlled according to the 
type of stimulus encountered. Transcripts that were not detected under any conditions 
were MIP-3(3. TCA-3, IFN-y, IL-18. IL-10 and IL-12p35 . The absence o f the Th2
cytokine IL-10 expression by chlamydial pulsed DC may further facilitate a Thl 
response.
Clearly, chlamydial pulsed DC differentially express several genes that encode 
proteins necessary for DC trafficking to the nodes, for recruitment of naive and activated 
a(3 T cells, y5 T cells, memory T cells, CD4+ T helper cells and CD8+ cytotoxic T cells. 
Chemical gradients provided by chlamydial pulsed DC allow for quick and efficient 
congregation o f the necessary cell types to elicit protective immunity. This permits 
crucial DC-T cell interactions to occur that are responsible for initiating a cascade o f 
cellular interactions whose products drive a predominant Thl immune response against 
chlamydiae. From these studies it was concluded that; (i) killed chlamydiae are potent 
transcriptional activators o f DC, (ii) gene expression by pulsed DC is temporally 
regulated, and (iii) transcriptionally activated genes encode proteins that promote DC 
migration and activation o f naive and effector T cells.
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(ii) Delivery of rMOMP to DC for Antigen Presentation
This work suggests that the DC is a crucial vehicle for the appropriate delivery of 
chlamydial Ags to elicit strong protective immunity against infection at the genital 
mucosa. Therefore it was hypothesized that the use of ex vivo activated bone marrow 
derived-DC could serve as a powerful vaccine delivery system to assess the immunizing 
properties o f targeted protective Ags against chlamydial genital infection. The chlamydial 
major outer membrane protein (MOMP) was selected to investigate this working 
hypothesis. The rationale for using MOMP is: (i) outer membrane preparations have 
been shown to elicit partial protection at the genital mucosa (83), (ii) MOMP is an 
immunodominant Ag and target of neutralizing antibodies (16), (iii) MOMP plays a role 
as a cytoadhesion thus is intimately linked to chlamydial pathogenesis (15). Certainly 
there are other potential surface or secreted antigens to investigate and the DC vaccine 
procedure could be utilized to screen these other target Ags as well.
Recombinant MOMP was produced in E.coli using a maltose binding protein 
(MBP) fusion system and purified on amylose columns (15). The particulate colloid 
spheres (30-40 nm) of MBP-MOMP fusion protein were used to pulse DC. 
Immunofluorescence and confocal microscopy show that DC phagocytized recombinant 
MOMP (rMOMP) as illustrated by positive staining for MOMP within the cytoplasm. 
The rMOMP contained high levels (-300,000 U/ml) of E.coli endotoxin (LPS). It was 
decided that the contaminating LPS would not be removed from the rMOMP due to the 
ability of LPS to increase the adjuvanticity of rMOMP. This strategy is supported by
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the FACS and RPA data (see Chapter 3) showing that LPS strongly stimulates DC 
maturation. The DC expression profile for cell surface Ags, chemokines and cytokines 
are identical in DC pulsed with either LPS or HK EB. Therefore, the contaminating LPS 
will likely provide the necessary stimuli for DC maturation that otherwise may not have 
occurred in the presence of recombinant protein alone. It is also known that LPS drives 
DC to secrete IL-12. an important Thl cytokine (72). DC pulsed with rMOMP secreted 
large amounts of IL-12 in vitro suggesting rMOMP pulsed DC have the potential to drive 
a strong Thl immune response following adoptive immunization.
It has been shown that adoptive transfer of infection sensitized T cells confers 
protection against chlamydial intravaginal challenge (37). Therefore, whether DC could 
process rMOMP and present epitopes to infection sensitized T cells was investigated 
next. It was found that infection sensitized T cells recognized DC bearing MOMP Ag(s) 
and were induced to proliferate. This suggests that DC process rMOMP and present 
epitopes necessary to stimulate memory T cell expansion in response to chlamydial re­
infection.
DC are known to phagocytose exogenous Ag with presentation onto MHC II. 
However, processed exogenous Ag can also cross over to the endogenous pathway for 
presentation onto MHC I. This process is termed ‘cross priming.' The mechanisms that 
control this phenomenon are not understood. Infection sensitized CD4+ and CD8+ T 
cells were incubated in the presence of pulsed DC to determine whether DC uptake of 
exogenous rMOMP led to Ag presentation on MHC I, MHC II or both molecules. The
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data show that infection sensitized CD4+ but not CD8+ T cells proliferated in response 
to DC presenting rMOMP Ag(s). Therefore, it was concluded that rMOMP Ag(s) were 
presented onto MHC II molecules and drive a CD4+ T cell response. Proliferation of 
infection sensitized CD4+ T cells in response to DC pulsed with the MBP portion of 
rMOMP was observed although at a significantly lower level.
Next, supernatants were collected from infection sensitized CD4+ T cells in the 
presence o f pulsed DC. The responding CD4 phenotype (Thl/Th2) was determined by 
measuring levels o f selected cytokines produced by the activated T cells. DC pulsed with 
rMOMP. but not MBP, induced infection sensitized CD4+ T cells to produce high levels 
of IFN-y. a known Thl cytokine. Conversely, lower levels (5X) of the Th2 cytokine IL-
10 were produced by T cells in the presence o f DC pulsed with rMOMP or MBP. IL-4, 
another Th2 secreted cytokine, was not detected. Therefore, the infection sensitized 
CD4+ T cells respond to rMOMP pulsed DC in a MOMP-specific manner with respect 
to IFN-y production. This MOMP specific response parallels the CD4 Thl response 
necessary for the clearance of genital chlamydial infection. From these results, it was 
concluded that rMOMP; (i) is readily endocytosed by DC, (ii) drives DC to secrete IL-12 
(iii) is processed and presented onto MHC II molecules, (iv) stimulates immune CD4+ 
but not CD8+ T cells to proliferate and, (v) promotes the production of IFN-y by 
activated CD4+ T cells.
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(iii) Immunization using DC pulsed with rMOMP
The in vitro data demonstrate that DC pulsed with rMOMP secrete very large 
amounts of IL-12 and present the appropriate epitopes to infection sensitized CD4+ Thl 
cells driving proliferation and secretion of IFN-y. Collectively, these data suggest that DC 
pulsed with rMOMP have the capacity to drive a potent anti-MOMP Thl immune 
response. Interestingly, adoptive immunization using DC pulsed with rMOMP elicited a 
Th2 immune response. CD4+ T cells from rMOMP immunized mice responded to EB 
Ag by secretion of IL-4 and IL-10, but not IFN-y. These mice also generated a 
predominant IgGl serum antibody response specific to the EB surface. This Th2 biased 
immune response failed to elicit protective immunity following chlamydial challenge.
In this work and as shown by others, ex vivo Ag pulsed DC used to adoptively 
immunize mice promote T cell production o f IL-10 (52, 84). In the case o f mice 
immunized with chlamydial pulsed DC, there is enhanced T cell secretion of IL-10 as 
compared to T cells obtained from chlamydial infected mice (52). However, T cells in 
both cases produce large amounts o f IFN-y and elicit an overall Thl biased response that
is protective following chlamydial challenge. IFN-y drives Thl responses and
concomitantly inhibits Th2 cells (85). T cell production of IFN-y in mice either infected
or immunized with chlamydial pulsed DC may serve to override the presence o f IL-10 
resulting an overall Thl response that is protective. T cell secretion o f IL-10 in rMOMP
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immunized mice, in the absence of IFN-y production, may be responsible for the observed 
Th2 response.
DC pulsed with rMOMP secrete large amounts of IL-12 suggesting these cells 
will potentially induce a Thl response following adoptive immunization. However, 
immunization using rMOMP pulsed DC induced a Th2 response. Recent studies 
demonstrated that IL-12 secreting DC. which promote Thl biased immune responses, 
were switched to DC that induced a Th2 response or T cell anergy (72). This observed 
switch is not currently understood, however it was shown to occur in response to IL-10. 
prostaglandin E2, or steroids. In the absence of IFN-y production, the secretion of IL-10 
in response to immunization using rMOMP pulsed DC may be sufficient to drive this 
switch and offers a possible explanation for the observed Th2 response.
T cells from infected mice or mice immunized with chlamydial pulsed DC did not 
secrete IL-4, a potent Th2 cytokine. In contrast, T cells obtained from mice immunized 
with DC pulsed with rMOMP secreted ~300 pg/ml of IL-4 and were not protected 
following chlamydial challenge. An IL-10 induced switch may possibly be responsible 
for DC activation o f  T cell differentiation into Th2 cells known to secrete cytokines such 
as IL-4. Perhaps, an IL-10 threshold has been met allowing the IL-12 secreting DC to 
switch to DC that induce differentiation into Th2 cells that secrete IL-4. T cell secretion 
of IL-4 was only observed in the mice immunized with DC pulsed with rMOMP lending 
support to the observed Th2 response in these mice.
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Although our rMOMP pulsed DC were primed ex vivo to drive a Thl response, 
following adoptive immunization the rMOMP pulsed DC elicited a potent Th2 response 
that was not protective. The complex nature of DC may require additional steps such as 
co-administration o f anti-lLlO receptor antibodies or anti-IL-4 receptor antibodies. 
Igietseme, et al ((84)) have shown increased efficacy of adoptive immunization using DC 
pulsed with HK EB in IL-10 KO mice. Abrogating an IL-10 response may allow DC 
pulsed with rMOMP to generate an appropriate Thl response following adoptive 
immunization. Alternatively, cytokine therapy using IFN-y may skew the immune 
response towards the needed Thl phenotype. It was concluded that delivery o f MOMP 
to DC for immunization and determination of protective capabilities is possible however 
the plasticity o f DC. with regard to the ability to drive a Thl versus Th2 response, will 
require additional measures to drive the appropriate response.
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Chapter 7: Summary and Conclusions
The need for a vaccine to control chlamydial sexually transmitted disease has been 
addressed in this work. The fact that conventional methods o f vaccination have failed to 
elicit protective immunity at the genital mucosa led to the study of a less conventional 
approach. This approach used ex vivo activated DC to vaccinate against chlamydial 
infection. The DC approach is currently the only known means to develop potent 
protective immunity against C. trachomatis at the genital tract other than infection. 
Protective immunity generated by infection or ex vivo antigen pulsed DC in a murine 
model correlates with a CD4+ Thl. IL-12 dependent immune response, however the 
precise effector mechanisms of this immunity are not understood (32.37.40,4!, 44. 86). In 
this work, the DC approach was characterized and manipulated in order to test the 
hypothesis that the use of ex vivo antigen pulsed DC could serve as a powerful vehicle 
for the delivery of individual chlamydial antigens that are thought to be targets for more 
conventional vaccine approaches. Chlamydial MOMP was selected as a target antigen to 
investigate.
Specific aims:
1. To characterize DC expression o f cell surface antigens, chemokines, chemokine 
receptors, and cytokines following pulsing with whole inactivated EBs
2. To deliver chlamydial MOMP to DC and elucidate the antigen 
processing/presentation pathways and the subsequent DC cytokine secretion 
profile.
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3. To immunize mice with MOMP pulsed DC and assess the protective 
capacities of chlamydial MOMP.
Conclusions:
1. DC pulsed with whole nonviable EBs upregulated cell surface expression of 
MHC II, CD86 and CD40.
2. DC pulsed with whole nonviable EBs differentially expressed M IP-la. MIP- 
2, TNF-a. IL-la. IL-1|3, IL-1RA, CCR7 between 2 - 4 8  hours; IP-10 and IL-6 
between 12-24  hours; MIP-3a and IL-12p40 between 1 2 - 4 8  hours.
3. DC efficiently phagocytized recombinant MOMP colloid spheres with 
subsequent secretion of large amounts of IL-12.
4. DC pulsed with recombinant MOMP presented MOMP antigens onto MHC 
II molecules and stimulated infection sensitized CD4+ T cells to proliferate 
and produce large amounts o f IFN-y.
5. The intravenous (infusion into the retro-orbital sinus) route o f DC vaccine 
administration was found to be superior to the subcutaneous and intra- 
peritoneal routes.
6. Variability in the levels of protective immunity generated by DC pulsed with 
whole inactivated EBs by intra-peritoneal injection correlated with chlamydial 
specific serum IgG2a antibody production.
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7. Adoptive immunization of DC pulsed with recombinant MOMP elicited a 
Th2 immune response as shown by:
(a) vaccine sensitized CD4+ T cell secretion of IL-4 and IL-10 in response 
to whole EB antigen
(b) production o f serum IgGl antibodies specific to the EB surface
8. Adoptive immunization of DC pulsed with recombinant MOMP was not 
protective following intra-vaginal chlamydial challenge.
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